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ABBREVIATIONS AND ACRONYMS
AV arteriovenous
CPG clinical practice guideline
CKD chronic kidney disease
CSN Canadian Society of Nephrology
DOPPS Dialysis Outcomes and Practice Patterns
Study
EBPG European Best Practice Guidelines
EDTNA/
ERCA
European Dialysis and Transplant Nurses
Association/European Renal Care
Association
ERBP European Renal Best Practice
ESKD end-stage kidney disease
ESVS European Society for Vascular Surgery
GEMAV Grupo Espa~nol Multidisciplinar del Acceso
Vascular
GRADE Grading of Recommendations Assessment,
Development and Evaluation
HR hazard ratio
IQR interquartile range
IRR incidence rate ratio
KDIGO Kidney Diseases: Improving Global
Outcomes
NKF-KDOQI National Kidney Foundation Kidney Diseases
Outcomes Quality Initiative
KHA-CARI Kidney Health Australia – Caring for
Australasians with Renal Insufﬁciency
MD mean difference
N number of
NICE National Institute for Health and Care
Excellence
OR odds ratio
PTFE polytetraﬂuoroethylene
RCT randomized controlled trial
RD risk difference
RR relative risk
95% CI 95% Conﬁdence Interval
SIGN Scottish Intercollegiate Guidelines Network
SD standard deviation
SMD standardized mean difference
UKRA UK Renal Association
VAS Vascular Access Society
DEFINITIONS
Interpreting evidence in the arteriovenous (AV) access litera-
ture is challenged by the heterogeneity in terminology and the
lack of standardization in outcomes. Below some of the terms
used in this guideline are listed and how they have been inter-
preted in the context of this document. Because guideline devel-
opment necessarily relies on aggregate data from systematic
reviews and other individual studies, we can only hope to pro-
vide the user with conceptual definitions for certain concepts
and outcome domains. At present, there is insufficient
consensus to go beyond that point and define specific outcome
measures or measurements.
AV access Overarching term referring to both AV ﬁs-
tulas and AV grafts.
AV access
thrombosis
Blood clot obstructing the AV access; indi-
cates loss of anatomic, haemodynamic and
clinical patency.
AV ﬁstula Surgically created autogenous vascular ac-
cess used for chronic haemodialysis consist-
ing of an anastomosis between an artery
and a vein, with the vein serving as the ac-
cessible conduit (synonym: native AV
ﬁstula).
AV graft Surgically created vascular access used for
chronic haemodialysis, whereby an artiﬁcial
or biological prosthetic segment is used to
connect an artery and a vein, with the pros-
thetic segment serving as the accessible
conduit.
Cannulation Placement of a dialysis needle in the AV ac-
cess to provide haemodialysis.
Clinical monitoring Clinical assessment of an AV access at regu-
lar intervals; it is distinct from technical sur-
veillance and includes examination of the
access AV thrill and bruit, haemostasis time
after needle removal and outﬂow appraisal
after arm elevation.
Clinical practice
guideline (CPG)
A set of statements that include recommen-
dations intended to optimize patient care,
which are informed by a systematic review
of evidence and an assessment of the bene-
ﬁts and harms of alternative care options
(synonym: guideline).
Maturation Process leading to a newly created AV access
being usable for haemodialysis; it encom-
passes enlargement and thickening of the
draining ﬁstula vein, increases in the blood
ﬂow and absence of thrombosis and bleeding
as mechanisms of AV access failure (syno-
nym: suitability for dialysis).
Recommendations Graded statements within a CPG intended
to optimize patient care that are informed
by a systematic review of evidence and an
assessment of the beneﬁts and harms of al-
ternative care options.
Patency See primary unassisted patency or second-
ary patency.
Pre-emptive intervention Intervention aimed at resolving a stenosis or
another problem in an AV access that is still
adequately providing dialysis; the intention
is to avoid the AV access becoming
dysfunctional.
Primary AV access
failure
An AV access that, despite radiological or
surgical intervention, cannot be used suc-
cessfully for dialysis by a given time point
(usually up to three months) following its
creation (synonym: dialysis suitability
failure).
Primary unassisted
patency
The time of AV access creation or place-
ment until any ﬁrst intervention (endovas-
cular or surgical) to maintain or restore
blood ﬂow or the ﬁrst occurrence to AV ac-
cess thrombosis (synonym: intervention-
free AV access survival; primary patency).
Secondary patency the time of AV access creation or placement
until AV access abandonment or permanent
Continued
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loss of the AV access (synonym: cumulative
AV access survival; secondary assisted
patency).
Surveillance Overarching term referring to both clinical
monitoring and technical surveillance of an
AV access; it includes haemodialysis param-
eters such as pump speed, dialyser inlet and
transmembrane pressure and indices of di-
alysis adequacy (Kt/V urea); sequential
measurements with trend analysis of intra-
access ﬂow, dynamic or static dialyser outlet
pressure, AV access recirculation or AV ac-
cess duplex ultrasound assessment.
Technical
surveillance
Assessment of an AV access at regular inter-
vals using a specialized apparatus; distinct
from clinical monitoring.
PREFACE
Vascular access remains one of the most challenging aspects of
renal replacement therapy. If the vascular access does not func-
tion properly, then haemodialysis will not remove uraemic re-
tention solutes adequately, and if all access possibilities have
been exhausted, then haemodialysis is no longer possible.
The consequences for patient survival may be severe if kidney
transplantation or peritoneal dialysis are not an option either.
Every professional who has been active in haemodialysis long
enough will remember at least a few patients in whom haemo-
dialysis had to be abandoned for lack of access. They will also
remember many more in whom a series of procedures was nec-
essary, often without ensuring adequate dialysis for prolonged
periods.
For patients, the ‘umbilical cord’ keeping them alive can be a
constant source of stressful experiences [1].
In 2007, during the second round of recommendations for
haemodialysis from the European Best Practice Guidelines
(EBPG)—the predecessor of the current European Renal Best
Practice (ERBP)—the first set of essentially clinically oriented
vascular access recommendations was drafted by a small group
of experts in vascular access surgery, interventional radiology
and haemodialysis [2]. Guideline development has changed
profoundly since then, with more rigorous methodology having
been introduced and a greater emphasis placed on evidence-
basedmedicine [3].
One of the caveats in the present clinical practice guideline
(CPG) is that even today high-quality data on vascular access
are scarce, partly because there are still too few sufficiently pow-
ered and well-designed controlled trials and partly because
adoption of evidence-based medicine in the field of vascular ac-
cess is maturing and changing the landscape. It is well recog-
nized that the heterogeneity of the patient samples studied and
the many associated confounders may bias the study results, in-
cluding differences in surgical procedures, skills and experience;
differences in patient education; variability in patient genetic
predisposition of thrombogenicity; variation in cannulation
procedures, uraemic status and vessel quality and many others.
It made offering strong treatment guidance difficult. However,
in addition to helping clinicians make decisions based on what
is known today, we hope this text will stimulate researchers to
explore what is still unknown and the nephrology community
at large to develop uniform definitions and assess more clini-
cally relevant vascular access outcomes [4].
This text is intended for nephrologists and for the other
stakeholders in the field whose participation was sought during
the development process: dialysis nurses, vascular access sur-
geons, radiologists, researchers, pharmacists and, importantly,
patients and their caregivers [5]. It specifically covers peri- and
postoperative care of AV fistulas and grafts. The second part—
under development when this guideline went to press—will
cover aspects related to access choice, preoperative vessel assess-
ment and central venous catheters. We hope the current and
planned CPG will assist the professional community in making
decisions about vascular access processes, pathways and care;
help patients and caregivers gain insight and facilitate joint
decision making in this field.
SUMMARY OF THE RECOMMENDATIONS
Chapter 1. Medical treatments for promoting
arteriovenous fistula maturation
1.1. We suggest any decision to give aspirin, ticlopidine or
clopidogrel in adults with end-stage kidney disease
(ESKD) during the ﬁrst 2 months after arteriovenous ﬁs-
tula creation for the sole purpose of improving matura-
tion must balance a reduction in thrombosis against
uncertain effects on maturation and bleeding. (2C)
1.2. We suggest any decision to give perioperative heparin
in adults with end-stage kidney disease during arteriove-
nous ﬁstula creation must balance an increase in arterio-
venous ﬁstula patency at 1 month against an important
increase in bleeding complications. (2C)
1.3. We suggest any decision to apply far infrared therapy in
adults with end-stage kidney disease during the ﬁrst 3
months after arteriovenous ﬁstula creation must balance
a possible reduction in thrombosis against uncertain
effects on maturation and bleeding. (2C)
1.4. There are insufﬁcient randomized controlled trial (RCT)
data to make a recommendation for ticagrelor, prasugrel,
dipyridamole, sulphinpyrazone, warfarin or other oral
anticoagulants, ﬁsh oil, statins, vonapanitase, glyceryl tri-
nitrate, iontophoretic injection of Salvia miltiorrhiza or
prednisolone for improving arteriovenous ﬁstula matura-
tion in adults with end-stage kidney disease. (-D)
Advice for clinical practice:
• Do not stop mono-antiplatelet treatment in adults under-
going AV access creation.
Chapter 2. Surgical and endovascular interventions for
promoting arteriovenous fistula maturation
2.1. We suggest using regional block anaesthesia rather than
local anaesthesia for arteriovenous ﬁstula creation in
adults with end-stage kidney disease. (2C)
2.2. We suggest there is insufﬁcient evidence to support end-
of-vein to side-of-artery over side-of-vein to side-of-
artery anastomosis for arteriovenous ﬁstula creation in
adults with end-stage kidney disease (2C)
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Chapter 3. Surgical and endovascular interventions for
non-maturing arteriovenous fistulas
3.1. We suggest there is insufﬁcient evidence to support open
surgical over endovascular interventions as the preferred
treatment for non-maturing arteriovenous ﬁstulas in
adults with end-stage kidney disease. (2D)
Advice for clinical practice:
• Decisions on how to treat non-maturing arteriovenous
ﬁstulas are likely best based on local resources, experience
and success rates.
• Institutions likely beneﬁt from building a dedicated multi-
disciplinary vascular access team, with clinical experience
in various techniques available for non-maturing arterio-
venous ﬁstulas.
Chapter 4. Self-administered interventions for
arteriovenous fistula maturation
4.1. We suggest that a standardized exercise programme in-
volving hand-and-arm exercises may improve arteriove-
nous ﬁstula maturation in adults with end-stage kidney
disease. (2C)
4.2. There is insufﬁcient evidence to support speciﬁc exercise
programmes or physical interventions to promote AV ﬁs-
tula maturation in adults with end-stage kidney disease.
(-D)
Advice for clinical practice:
• Involving patients more actively in preparing for haemo-
dialysis may improve self-management skills and health
literacy and thereby well-being.
Chapter 5. Perioperative prophylactic antibiotics for
preventing arteriovenous access infection
5.1. We recommend giving preoperative antibiotic prophy-
laxis for arteriovenous graft insertion in adults with end-
stage kidney disease. (1C)
5.2. We suggest giving preoperative antibiotic prophylaxis for
complex arteriovenous access procedures in adults with
end-stage kidney disease. (2D)
5.3. We suggest not giving preoperative antibiotic prophylaxis
for simple arteriovenous access procedures in adults with
end-stage kidney disease. (2D)
Advice for clinical practice:
• Simple arteriovenous access procedures include the crea-
tion of a native radiocephalic or native brachiocephalic ar-
teriovenous ﬁstula.
• Complex arteriovenous access procedures include those
that are not considered simple.
Chapter 6. Timing of first cannulation
Arteriovenous fistulas
6.1. In adults requiring haemodialysis, we suggest arteriove-
nous ﬁstulas can be cannulated 4 weeks after creation if
they are considered suitable for cannulation on clinical
examination. (2C)
6.2. In adults requiring haemodialysis, we recommend against
cannulating arteriovenous ﬁstulas sooner than 2 weeks af-
ter their creation. (1B)
6.3. In adults requiring haemodialysis, we suggest against can-
nulating arteriovenous ﬁstulas 2–4 weeks after their crea-
tion unless this will avoid placement of a central venous
catheter for haemodialysis. (2C)
Arteriovenous grafts
6.4. In adults requiring haemodialysis, we recommend that
‘early cannulation type’ arteriovenous grafts can be can-
nulated as soon as wound healing permits. (1B)
6.5. In adults requiring haemodialysis, we suggest against can-
nulating a ‘standard type’ arteriovenous graft sooner than
2 weeks after insertion unless this will avoid placement of
a central venous catheter for haemodialysis. (2B)
Advice for clinical practice:
• In practice, suitability for cannulation on clinical exami-
nation is determined by the presence of a palpable vein
and good thrill.
• If clinical examination is inconclusive, then ultrasound
with ﬂow measurement may help in deciding whether to
cannulate.
• Bedside ultrasound-guided cannulation may be helpful in
avoiding complications and decreasing the number of
failed cannulations.
• Using single-needle dialysis, low dialysis blood ﬂows and
smaller needles (17 gauge) may prevent harm to arterio-
venous ﬁstulas that are cannulated early.
• Wound healing refers to the tissue around the body of the
graft rather than the incision site.
Chapter 7. Vascular access surveillance
Arteriovenous fistulas
7.1. We suggest the evidence for technical surveillance in addi-
tion to clinical monitoring of a functional arteriovenous
fistula to detect and pre-emptively correct a haemodynami-
cally important arteriovenous access stenosis in adults is in-
conclusive and needs more research. (2C)
Arteriovenous grafts
7.2. We suggest against technical surveillance in addition to
clinical monitoring of a functional arteriovenous graft to
detect and pre-emptively correct a haemodynamically im-
portant arteriovenous access stenosis in adults unless it
occurs in the context of a clinical study. (2C)
Chapter 8. Medical treatments for maintaining long-term
arteriovenous access patency
Arteriovenous fistulas
8.1. We suggest any decision to give ﬁsh oil to adults with
end-stage kidney disease in the year following arteriove-
nous ﬁstula creation must balance improved patency at 1
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year against an unknown risk of bleeding and other side
effects. (2C)
8.2. We suggest far infrared therapy may be considered for
improving long-term arteriovenous ﬁstula patency in
adults with end-stage kidney disease. (2C)
8.3. There are insufﬁcient randomized controlled trial data to
make a recommendation for aspirin, clopidogrel, ticlopi-
dine, warfarin, sulphinpyrazone, vonapanitase, beraprost
sodium, cholecalciferol, statins, dipyridamole or dipyrida-
mole combined with aspirin to be given for maintaining
long-term arteriovenous ﬁstula patency in adults with
end-stage kidney disease. (-D)
Arteriovenous grafts
8.4. We recommend against warfarin in combination with
antiplatelet agents and against clopidogrel in combina-
tion with high-dose aspirin for reducing arteriovenous
graft thrombosis in adults with end-stage kidney disease.
(1C)
8.5. We suggest any decision to give ﬁsh oil in the year follow-
ing arteriovenous graft creation in adults with end-stage
kidney disease must balance any improvement in graft
patency at 1 year against an unknown risk of bleeding.
(2C)
8.6. There are insufﬁcient randomized controlled trial data to
make a recommendation for aspirin, clopidogrel, ticlopi-
dine, warfarin, beraprost sodium, statins, dipyridamole or
dipyridamole combined with aspirin to be given for
maintaining long-term arteriovenous graft patency in
adults with end-stage kidney disease. (-D)
Chapter 9. Cannulation techniques for arteriovenous
fistulas
9.1. We suggest against using the area technique for cannu-
lating arteriovenous ﬁstulas in adults treated with haemo-
dialysis. (2D)
9.2. We suggest using either a rope-ladder or buttonhole tech-
nique for cannulating arteriovenous ﬁstulas in adults
treated with haemodialysis and letting the choice be de-
pendent on local expertise and arteriovenous ﬁstula char-
acteristics. (2D)
Advice for clinical practice:
• Antiseptic measures and practical aspects of the cannula-
tion procedure are important in reducing the infection
risk associated with buttonhole cannulation.
• Arteriovenous grafts are usually only cannulated using a
rope-ladder technique.
Chapter 10. Needle types for arteriovenous fistulas
10.1. We suggest using either sharp needles or plastic cannu-
las for cannulating arteriovenous ﬁstulas in adults
treated with haemodialysis. (2C)
10.2. We recommend using blunt needles only for buttonhole
cannulation of arteriovenous ﬁstulas in adults treated
with haemodialysis. (1D)
Advice for clinical practice:
• A quality improvement programme including recording and
monitoring of the needle types and cannulation techniques
alongside arteriovenous access outcomes can help to moni-
tor quality, guide changes in cannulation practice, if needed,
and improve quality of vascular access care.
• Arteriovenous grafts are usually only cannulated using
sharp steel needles.
Chapter 11. Timing of intervention for arteriovenous
fistula thrombosis
11.1. We suggest attempting to declot a thrombosed arterio-
venous ﬁstula in adults as soon as possible under opti-
mal conditions and before the next haemodialysis
treatment. (2D)
11.2. We suggest attempting to declot a thrombosed arterio-
venous ﬁstula in adults even if there has been a delay of
days to weeks. (2D)
Chapter 12. Surgical and endovascular interventions for
arteriovenous access thrombosis
12.1. We suggest the choice between surgical and endovascular
interventions for arteriovenous access thrombosis be
defined by the condition of the patient and their vascular
access, as well as local expertise, as there is no evidence
one approach improves outcomes over another. (2B)
COMPOSITION OF THE GUIDELINE
DEVELOPMENT GROUP
ERBP’s Advisory Board appointed the co-chairs and invited a
small group of content experts to a steering committee to direct
the guideline development process. These content experts were
chosen based on their previous involvement with EBPG or their
close association with national or international vascular access
societies [3]. The group was supplemented with selected mem-
bers of ERBP’s methods support team to supervise the project
and provide methodological expertise in guideline development
throughout the process. The steering committee convened in
May 2013 and February 2014 and decided on the composition
of the Guideline Development Group (GDG), taking into ac-
count the clinical and research expertise of each proposed can-
didate and their willingness to invest the necessary time and
effort to perform the task according to the proposed deadlines
and the agreed methodology. The group ultimately consisted of
44 participants, including 25 nephrologists, 9 surgeons, 3 radiolog-
ists, 5 researchers, 2 nurses and 8 methodologists (categories not
mutually exclusive). It included 29 men and 15 women (see
Supplement 1—Guideline Development Group area of expertise).
Guideline Development Group
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PURPOSE AND SCOPE OF THIS GUIDELINE
Topic selection
The process of identifying and prioritizing all relevant treat-
ment decisions along the vascular access care pathway (vascular
access ‘topics’) comprised three phases [5]. In Phase 0, we cre-
ated a preliminary list of topics based on the literature review
and input from a multidisciplinary expert group. Its members
did not necessarily participate in later stages of the guideline de-
velopment process. The group consisted of two kidney patients,
two nephrologists, a renal nurse, two surgeons and a radiologist.
In Phase 1, an international panel of 85 kidney patients, 687
nephrologists, 194 nurses and 140 surgeons/radiologists rated
the priority of these topics on a 5-point Likert scale through an
online survey and suggested additional topics to complement
the preliminary list. The additional topics were prioritized in
Phase 2 by rating 42 vascular access–related topics on a 5-point
Likert scale in an electronic questionnaire. Details of the scop-
ing procedures and its results have been published separately
[5].
The group estimated that it would be feasible to select 20
topics for further elaboration and selected these from the list of
42 topics, guided by a preference for prioritizing topics that had
been covered by EBPG and by the priority ratings they had re-
ceived from patients and clinicians in the scoping procedure
[2]. Although the group initially developed all 20 topics simulta-
neously, the guideline was later split into two parts for reasons
of feasibility.
Why was this guideline produced?
The purpose of this CPG was to provide guidance on the
management and preservation of AV fistulas and grafts for hae-
modialysis. It was designed to provide information and assist
decision making related to this topic. It was not intended to pre-
scribe a standard of care and should not be construed as such. It
should also not be interpreted as prescribing an exclusive course
of management.
This CPG was developed by ERBP, the guidance body of
the European Renal Association–European Dialysis and
Transplant Association (ERA-EDTA) and is a collaborative ef-
fort of various stakeholders within the field, including represen-
tatives of the Vascular Access Society (VAS), nephrologists,
vascular access surgeons, radiologists, dialysis nurses, research-
ers, patients and their caregivers.
All these stakeholders agreed that there was a need for up-
to-date guidance on vascular access management. The current
document is an update of EBPG for haemodialysis published in
2007 [2]. An attempt to adhere to increasingly stringent guide-
line development methodology has required certain sacrifices
in terms of scope. As a result, the current document does not
necessarily cover the same topics as the previous version. Some
are shared, but some were archived in favour of new questions
peri-and postoperative care of AV fistulas and grafts ii7
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prioritized by both health care providers and the people they
care for [5].
Who is this guideline for?
This guideline aims to support clinical decision making for
any health care professional treating or caring for haemodialysis
vascular access, including nephrologists, vascular access sur-
geons, radiologists, dialysis nurses and pharmacists dealing
with vascular access in both outpatient and in-hospital settings
and general practitioners, internists and surgeons who are not
directly practicing in the nephrology or dialysis access field but
who may be confronted indirectly with haemodialysis access
issues and systems.
The guideline is also developed for policymakers, for inform-
ing standards of care at national and international levels, and
for haemodialysis patients, to improve their views on what dial-
ysis access is about and how they can participate in its mainte-
nance and preservation.
What is this guideline about?
This CPG covers aspects related to vascular access that are
necessary for successful long-term haemodialysis. A rigorous
multilayered phased selection procedure drove identification of
the specific clinical questions this guideline aims to answer [5].
Population
The guideline covers aspects related to vascular access that
are necessary for successful chronic haemodialysis in adults of
all ages with ESKD. It does not cover vascular access in children
because the GDG felt essential differences exist between the two
patient groups, requiring a targeted guideline development pro-
cess. Not only would priorities for guideline development likely
differ, interventions would have an appreciably different risk–
benefit balance and require exploration of lower-level evidence
generated specifically in children, which would be beyond the
limits of our resources available at present.
Conditions
This guideline covers aspects related to maturation and
maintenance of AV fistulas and grafts used in long-term hae-
modialysis. It specifically deals with interventions for promot-
ing maturation of the AV access, perioperative antibiotic
therapy for preventing AV access infection, timing of first can-
nulation, cannulation techniques and needle types, medical
treatments for long-term AV access patency, AV access surveil-
lance and pre-emptive intervention and surgical and endovas-
cular interventions for AV access thrombosis.
Health care setting
This guideline targets outpatient, in-hospital and out-of-
hospital haemodialysis unit settings dealing with adults who
need to have an AV access for long-term haemodialysis.
Clinical management
This guideline deals with educational, pharmaceutical and
interventional tools for promoting successful use of an AV ac-
cess and interventions aimed at preventing failure of the vascu-
lar access by the use of specific treatment strategies tailored to
the underlying problem. This guideline covers treatment for
adults with acute or chronic vascular access problems and strat-
egies to prevent or treat, regardless of the underlying cause of
kidney disease, any pre-existing systemic vascular condition or
any specific haemodialysis strategy.
In line with the mission statement of ERBP, this guidance
document intends to inform all involved stakeholders and to
stimulate shared decision making. It also highlights topics for
which additional research data are needed and offers sugges-
tions for how research might be pursued [3].
METHODS FOR GUIDELINE DEVELOPMENT
Establishment of the GDG
A steering committee consisting of the chair of ERBP at that
time (Wim Van Biesen), selected members of ERBP’s methods
support team (Christiane Drechsler, Maria Haller, Muguet
Koobasi, Evi Nagler and Sabine van der Veer), the co-chairs of
the GDG appointed by ERBP’s Advisory Board (Maurizio
Gallieni and Anna Marti I Monros) and selected content
experts (Markus Hollenbeck, Nicholas Inston, Mick
Kumwenda, Steve Powell, Jan Tordoir, Matthias Widmer) con-
vened inMay 2013 and February 2014 and decided on the com-
position of the GDG, taking into account the clinical and
research expertise of the proposed candidates. The GDG con-
sisted of content experts that included individuals with exper-
tise in vascular access. In its composition, the GDG aimed to be
multidisciplinary, including nephrologists, surgeons, radiolog-
ists, researchers, a nurse and a patient. ERBP’s methods support
team provided methodological input and practical assistance
throughout the guideline development process.
Developing clinical questions
With the scope of the guideline as the point of departure, the
GDG identified specific clinical research questions for which a
systematic review was conducted.
Development of review questions
The methods support team assisted in developing review
questions, that is, framing the clinical questions into a search-
able format, by applying the PICO procedure. This required
careful specification of the patient group (P), the intervention
(I), the comparator (C) and the outcomes (O) for intervention
questions and the patient group, index tests, reference standards
and target conditions for questions of diagnostic test accuracy
[6]. For each question, the GDG agreed upon explicit review
question criteria, including study design features (see
Supplement 3 for detailed review questions and PICO tables).
Assessment of the relative importance of the outcomes
For each intervention question, the GDG compiled a list of
outcomes, reflecting both benefits and harms of alternative
management strategies. The GDG ranked the outcomes as criti-
cal, highly or moderately important according to their relative
importance in the decision-making process. As such, patient-
important health outcomes, such as patient survival and quality
of life, as well as permanent loss of the vascular access, were
ii8 M. Gallieni et al.
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considered critical. Outcomes such as AV access thrombosis,
infections, hospitalizations and temporary central venous hae-
modialysis catheter use were considered highly important, but
less important than the critically important clinical outcomes
(Table 1).
Target population perspectives
Efforts were made to capture the target population’s per-
spectives by adopting three strategies.
To identify and prioritize all relevant treatment decisions
along the vascular access care pathway (vascular access ‘topics’),
we conducted an extensive survey in three phases, including
participants with kidney disease in every phase of the process
[5]. We ultimately elicited responses from 85 patients residing
in Austria (15%), Belgium (24%), Spain (14%), The
Netherlands (29%) and the UK (18%).
Second, one of the GDG members, a researcher in the field
of vascular access and actively involved with the evidence re-
view and guideline development process, had previously been
treated with chronic haemodialysis and, as such, was very famil-
iar with many of the challenges faced by people with ESKD.
Third, ERBP has a permanent patient representative on its
board. Although he was not included in the GDG or in the evi-
dence review process, drafts of the guideline document were
sent out for his review and his comments were considered in re-
vising and drafting the final document.
Searching for evidence
Sources and search strategy
We used a hierarchical strategy whereby the ERBP’s meth-
ods support team first searched the Cochrane Database of
Systematic Reviews (up to April 2018) for reviews that were ei-
ther up to date or could be updated by our review team. If such
a review did not exist, then the methods support team subse-
quently searched Database of Abstracts of Reviews of Effects
(DARE) (up to April 2018) Cochrane Controlled Register of
Trials (CENTRAL) (up to April 2018) for other systematic
reviews and randomized trials, respectively. If no randomized
trials were available, then an additional search was conducted
in MEDLINE (up to April 2018) for identifying non-random-
ized studies that fit the inclusion criteria set for each research
question.
Search strategies combined subject headings and text words
for the patient population and intervention. The detailed search
strategies and dates are available in Supplement 4—Search
strategies.
Study selection
We used the Early Reference Organisation Software (http://
www.eros-systematic-review.org) to organize the initial step of
screening and selection of papers. The title and abstract of all
papers retrieved by the search were made available to those re-
sponsible for screening through this system. For each research
question, two GDG members independently screened all titles
and abstracts. Abstracts that did not meet the inclusion criteria
were discarded. Any discrepancies at this stage were resolved by
group consensus.
In a second step, the methods support team retrieved full
texts of potentially relevant studies and two mutually indepen-
dent reviewers examined them for eligibility, according to the
preset eligibility criteria independent of each other. Any dis-
crepancies were resolved by consensus. If no consensus could
be reached, then the disagreement was settled by group
arbitrage.
The flow diagram depicting the paper selection process for
each research question is presented in Supplement 5—Study se-
lection and flow diagrams.
Data extraction and critical appraisal of individual studies
For each included study we collected relevant information
on design, conduct and relevant results through standardized
data extraction forms. These forms were developed in
Salesforce (Salesforce, San Francisco, CA, USA), a customer re-
lationship platform, customized to fit our needs. We introduced
closed questions with drop-down answer lists whenever possi-
ble to improve data quality. The tool allowed automatic collec-
tion of the entered data into a database and semi-automatic
cross-checking of the data independently entered by two
reviewers. It also facilitated the generation of the summary evi-
dence tables directly from the collated dataset. As no data re-
quired manual copying into a different format after it has been
entered by the reviewer, we believed this would reduce error in
handling of the data. For each question, two reviewers extracted
all data independent of each other. The methods support team
produced tables displaying the extracted data for both reviewers
by question. The member of the methods support team checked
all the data and any discrepancies were discussed and resolved
by consensus, and if no consensus could be reached, disagree-
ments were resolved by an independent referee. From these
tables we produced merged consensus evidence tables for
informing the recommendations. The summary evidence
tables are available from Supplement 6—Summary evidence
tables.
The risk of bias of the included studies was evaluated using
various validated checklists as recommended by the Cochrane
Collaboration. These were Assessing the Methodological
Quality of Systematic Reviews (AMSTAR) for systematic
reviews [7], the Cochrane Risk of Bias tool 2.0 for RCTs [8], the
Newcastle-Ottawa scale for cohort and case–control studies [9]
and Quality Assessment of Diagnostic Accuracy Studies
(QUADAS) for diagnostic test accuracy studies [10]. Data were
compiled centrally by ERBP’s methods support team.
Table 1. Hierarchy of outcomes
Hierarchy Outcomes
Critically important Death
Technique/vascular access failure, major cardio-
vascular events, major infections, quality of life,
uninterrupted dialysis sessions
Highly important Hospitalization, pain, physical limitations, blood
ﬂow (in AV access or in dialysis machine)
Moderately
important
Anxiety/distress, pressures (in AV access or in
dialysis machine), dialysis adequacy,
recirculation
peri-and postoperative care of AV fistulas and grafts ii9
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Rating the quality of the evidence for each outcome across
studies
The evidence for outcomes on therapeutic interventions
from the included systematic reviews of randomized trials was
assessed using the Grading of Recommendations Assessment,
Development and Evaluation (GRADE) toolbox developed by
the international GRADE working group [11]. In accordance
with GRADE, the GDG initially categorized the quality of the
evidence for each outcome as high if it originated predomi-
nantly from RCTs and low if it originated from observational
data. The quality of the evidence was subsequently downgraded
one or two levels if results from individual studies were at seri-
ous or very serious risk of bias, there were serious inconsisten-
cies in the results across studies, the evidence was indirect, the
data were sparse or imprecise or publication bias was thought
to be likely. If evidence arose from observational data, but effect
sizes were large, then there was evidence of a dose–response
gradient, or all plausible confounding would either reduce a
demonstrated effect or suggest a spurious effect when results
showed no effect, the quality of the evidence would be upgraded
(Table 2). Uncontrolled case series and case reports automati-
cally received downgrading from ‘low’ to ‘very low’ level of evi-
dence for risk of bias, so that no further reasons for
downgrading were checked. By repeating this procedure, an
overall quality of evidence for each outcome and each interven-
tion was obtained. See Table 3 for the list of definitions [12].
Formulating statements and grading recommendations
Recommendations
After the summary tables were prepared and the evidence
assessed, recommendations were formulated and graded.
Recommendations can be in favour of or against a certain strat-
egy. The GDG drafted the recommendations based on their in-
terpretation of the available evidence. Judgements around four
key factors determined the strength of the recommendation:
the balance between desirable and undesirable consequences of
alternative therapeutic or diagnostic strategies, the quality of
the evidence and the variability in values and preferences.
Formal decision or cost analysis was not conducted. In accor-
dance with GRADE, the strength of the recommendations was
classified as strong, coded ‘1’, or weak, coded ‘2’ (Table 4) [11].
The strength of a recommendation is determined not only by
the certainty of evidence, but also by other, often complex
judgements regarding the size of the net medical benefit, values
and preferences and costs. Individual statements were made
and discussed to reach a group consensus.
Advice for clinical practice
An additional category of ungraded statements was used for
areas where formal evidence was not sought and statements
were based on common sense or expert experience alone. These
were termed ‘advice for clinical practice’ to differentiate them
from graded recommendations and do not hold an indicator
for the quality of the evidence. Advice for clinical practice is
only for improving practical implementation. It contains some
elaboration on one of the statements, clarifying how the state-
ment can be implemented in clinical practice. The ungraded
statements were generally written as simple declarative state-
ments but were not meant to be stronger than level 1 or 2
recommendations.
Table 2. Method of rating the certainty of the evidence for an outcome
Step 1: starting grade
according to study design
Step 2: lower if Step 3: higher if Step 4: determine final grade for quality of
evidence
Randomized trials ¼ High
Observational studies ¼ low
Risk of bias
1 Serious
2 Very serious
Inconsistency
1 Serious
2 Very serious
Indirectness
1 Serious
2 Very serious
Imprecision
1 Serious
2 Very serious
Publication bias
1 Likely
2 very likely
Large effect
þ1 Large
þ2 Very large
Dose response
þ1 Evidence of a gradient
All plausible confounding
þ1 Would reduce a demonstrated effect
þ1 Would suggest a spurious effect
when results show no effect
High (four plus: þþþþ)
Moderate (three plus: þþþ)
Low (two plus: þþ)
Very low (one plus: þ)
Adapted from Balshem et al. J Clin Epidemiol 2011; 46: 401–406 [12].
Table 3. Grade for the overall certainty of evidence
Grade Quality level Definition
A High We are conﬁdent that the true effects lie
close to that of the estimates of the effect
B Moderate The true effects are likely to be close to
the estimates of the effects, but there is a
possibility that they are substantially
different
C Low The true effects might be substantially
different from the estimates of effects
D Very low The estimates are very uncertain, and of-
ten will be far from the truth
Adapted from Guyatt et al. [11].
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Writing rationale
Recommendations and advice for clinical practice for
each of the clinical questions were collated in separate chapters
structured according to a specific format. Each question
resulted in one or more specific boxed statements. Within
each recommendation, the strength was indicated as level 1 o
level 2 and the quality of the supporting evidence as A, B, C or
D as prescribed by the GRADE methodology (Tables 3 and 4)
[11]. These statements are followed by advice for clinical prac-
tice and the rationale. The rationale contains a brief section
with relevant background and justification of the topic, followed
by a short narrative review of the evidence and finally a justifi-
cation of how the evidence was translated in the recommenda-
tions made. When areas of uncertainty were identified, the
GDG considered making suggestions for future research based
on the importance to patients or the public and on ethical and
technical feasibility. Finally, each chapter provides an overview
of recommendations made by other guideline bodies. The list is
not meant to be exhaustive, but rather is intended to provide a
concise overview of other recommendations made. Any grading
was reprinted as reported in the respective clinical practice
guideline. These may and do differ for some organizations from
the GRADE system used for the ERBP guideline development
process. The reader is referred to the original publication for
further details regarding the grading system for coding individ-
ual recommendations.
Internal and external review
Internal review
Both the VAS and ERBP nominated experts in vascular ac-
cess and members of their governance bodies. Internal referees
were asked to complete a standardized internal review survey
online (see Supplement 7—Internal review). Referees were
asked whether statements were clear, implementable and to
what extent they agreed with the content on a scale of 1–5.
These scores were averaged and colour-coded from red (1) to
green (5) to help visualize problematic areas. In addition, inter-
nal reviewers were asked to comment on the statements and the
rationale within free-text fields. All these comments and sugges-
tions were discussed with the GDG group. For each comment
or suggestion, the GDG evaluated if the statement needed to be
adapted, again considering the balance between desirable and
undesirable consequences of the alternative management strate-
gies, the quality of the evidence and the variability in values and
preferences.
External review
The draft guideline was posted on the ERBP website and the
public was invited to comment using the same standardized re-
view form as was used for the internal review process. Anyone
was invited to comment, but reviewers had to provide basic in-
formation to identify their background or stakeholder position.
The public consultation period lasted for 4 weeks to ensure ade-
quate time for responses. In addition to public consultation, the
guideline was sent to the council of the ERA-EDTA, the VAS,
Kidney Diseases: Improving Global Outcomes (KDIGO),
Kidney Health Australia – Caring for Australasians with Renal
Impairment (KHA-CARI), the National Institute for Health
and Care Excellence (NICE), the European Dialysis and
Transplant Nurses Association/European Renal Care
Association and the European Society of Vascular Surgery
(ESVS) for review. Referees used the same standardized review
form as for the internal review process. All comments were
summarized by ERBP’s methods support team and provided to
the guideline group chair to determine the appropriate course
of action as part of finalizing the guidelines. As part of the final
approval process, the ERBP chair and co-chair ensured that all
comments had been appropriately addressed.
Timeline and procedure for updating the guideline
ERBP aims to update its clinical practice guidelines at least
every 5 years. New evidence requiring additional recommenda-
tions or changes to existing statements could instigate an earlier
update. At least every 5 years, ERBP’s methods support team
will aim to update its literature searches. Relevant studies will
be identified and their data will be extracted using the same pro-
cedure as for the initial guideline. During a 1-day meeting, the
GDG will decide whether the original statements require updat-
ing. ERBP will aim to publish an updated version of the guide-
line online.
Table 4. Implications of strong and weak recommendations for stakeholders
Implications
Grade Patients Clinicians Policy
1—strong ‘We recommend’ Most people in your situation would
want the recommended course of ac-
tion, only a small proportion would
not
Most patients should receive the rec-
ommended course of action
The recommendation can be
adopted as a policy in most
situations
2—weak ‘We suggest’ Most people in your situation would
want the recommended course of ac-
tion, but many would not
You should recognize that different
choices will be appropriate for differ-
ent patients
Policymaking will require sub-
stantial debate and involvement of
many stakeholders
You must help each patient to ar-
rive at a management decision
consistent with her or his values
and preferences
Adapted from Guyatt et al. [11].
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CHAPTER 1 . MEDICAL TREATMENTS FOR
PROMOTING AV FISTULA MATURATION
Recommendations
We suggest any decision to give aspirin, ticlopidine or
clopidogrel in adults with end-stage kidney disease dur-
ing the ﬁrst 2 months after arteriovenous ﬁstula creation
for the sole purpose of improving maturation must bal-
ance a reduction in thrombosis against uncertain effects
on maturation and bleeding. (2C)
We suggest any decision to give perioperative heparin
in adults with end-stage kidney disease during arteriove-
nous ﬁstula creation must balance an increase in arte-
riovenous ﬁstula patency at 1 month against an impor-
tant increase in bleeding complications. (2C)
We suggest any decision to apply far infrared therapy
in adults with end-stage kidney disease during the ﬁrst
3 months after arteriovenous ﬁstula creation must bal-
ance a possible reduction in thrombosis against uncer-
tain effects on maturation and bleeding. (2C)
There are insufﬁcient randomized controlled trial data to
make a recommendation for ticagrelor, prasugrel, dipyri-
damole, sulphinpyrazone warfarin or other oral anticoa-
gulants, ﬁsh oil, statins, vonapanitase, glyceryl trinitrate,
iontophoretic injection of Salvia miltiorrhiza or predniso-
lone for improving arteriovenous ﬁstula maturation in
adults with end-stage kidney disease. (-D)
Advice for clinical practice:
• Do not stop mono-antiplatelet treatment in adults under-
going AV access creation.
Rationale
• Background
Non-maturation is defined as a process leading to a newly cre-
ated AV access that cannot be used for haemodialysis; it does
not apply to AV grafts. Non-maturation may cause various
problems, such as a need for reintervention or for a temporary
central venous haemodialysis catheter to be inserted. An AV fis-
tula may fail because of thrombosis or because of the feeding ar-
tery or the draining vein failing to enlarge. Medications that
influence these processes could result in improvement of matu-
ration, provided their adverse effects do not counterbalance
their benefits either locally or systemically. For instance, antico-
agulant and antithrombotic agents may prevent clotting, but
they may also cause bleeding. Vasoactive agents may prevent
vasospasm, stimulate vasodilation and increase blood flow in
the newly created AV fistula, but they may also lower systemic
blood pressure. As maturation problems in the first months may
result from different pathophysiological mechanisms rather than
patency problems in the longer term, the two issues are discussed
in two different chapters of this guideline. The current chapter
specifically covers AV fistula maturation. Chapter 8 covers long-
term patency of AV fistulas and AV grafts.
• Summary of the evidence
(Supplement 3 j Review questions – PICO format—Chapter 1)
(Supplement 4j Search strategies—Chapter 1)
(Supplement 5j Study selection flow diagrams—Chapter 1)
(Supplement 6j Summary evidence tables—Chapter 1)
We identified seven systematic reviews of RCTs assessing
benefits and harms of various medical adjuvant treatments to
increase overall patency of AV fistulas and AV grafts [13–19].
All these reviews were judged to be of moderate to high quality
with AMSTAR scores of 8–10/11. The reviews included studies
measuring maturation outcomes after 6–12weeks and patency
outcomes measured several months later. Unfortunately the
meta-analyses did not separate studies reporting maturation
outcomes from studies reporting longer-term patency out-
comes. The next paragraph describes the nature and the content
of the included systematic reviews that were used to identify rel-
evant randomized trials. Based on group consensus, for this
chapter we chose to only consider RCTs and meta-analyses
measuring patency outcomes before or at 12weeks as an arbi-
trary cut-off to distinguish maturation from long-term patency
and only in those studies assessing AV fistulas.
The first was a Cochrane systematic review with content
assessed as being up to date through 23 March 2015 [14]. It in-
cluded 15 RCTs comprising 2230 participants at the time of ac-
cess creation. Seven trials included patients with an AV fistula,
six with an AV graft and two with either an AV fistula or an AV
graft. All but one enrolled participants at the time of AV access
creation [20]. Tested medical interventions included aspirin,
ticlopidine, dipyridamole, dipyridamole plus aspirin, warfarin,
fish oil, clopidogrel, sulphinpyrazone and human type I pancre-
atic elastase (vonapanitase). Studies mostly included partici-
pants of all ages and follow-up ranged from 1 to 18months
after AV access insertion. Most studies only assessed AV access
thrombosis as the primary outcome of interest.
The second was also a Cochrane systematic review, which
specifically covered antiplatelet agents to prevent vascular ac-
cess failure and other outcomes in people with chronic kidney
disease (CKD). Its content was assessed as being up to date
through 24 January 2011 [15]. The review included 12 RCTs
assessing the effect of antiplatelet agents in a newly created AV
access and another 9 in an already functioning AV access. Nine
of these were also included in the first review [14]. Of the
remaining three studies, the largest was excluded [21]. The RCT
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tested dipyridamole plus aspirin versus placebo, but included par-
ticipants in whom aspirin was started prior to study inclusion and
did not require discontinuation in the placebo group. The other
two did not contribute to any of the meta-analyses of interest [22,
23]. Medical interventions included aspirin, ticlopidine, dipyrida-
mole, dipyridamole plus aspirin, clopidogrel and sulphinpyrazone
[15]. The Cochrane review resulted in a derivative review assess-
ing only vascular access outcomes [13].
Four other systematic reviews each assessed a specific treat-
ment, such as fish oil [16], far infrared therapy [17, 18] or intra-
operative anticoagulation during AV access formation [19].
In addition to these reviews, we identified six RCTs pub-
lished after 2013 and not included in any of the considered sys-
tematic reviews, assessing various adjuvant medical treatments
for improving AV access patency [24–29].
Antiplatelet agents
Palmer et al. found that, overall, antiplatelet agents seemed to
reduce AV fistula thrombosis at 8 weeks, although the certainty
of the evidence was compromised by risk of bias in the underly-
ing studies and serious imprecision, with a total sample size be-
low the optimal information size {five RCTs; n¼ 1005; relative
risk [RR] 0.43 [95% Confidence Interval (CI) 0.26–0.73]; I
square (I2) ¼ 25%} [13]. Effects on AV fistula maturation fail-
ure were uncertain [two RCTs; n¼ 794; RR 0.57 (95% CI 0.13–
2.51)]. Definitions for AV fistula maturation varied widely.
Aspirin
One RCT compared 500mg of aspirin versus placebo given the
day before until 28 days after construction of a Brescia–Cimino
fistula in 92 patients [30]. Aspirin reduced AV fistula thrombo-
sis at 1 month by 81% [n¼ 92; RR 0.19 (95% CI 0.04–0.81)].
The sample size was low and risk of bias unclear. Numerically,
more people complained of gastric pain and epistaxis in those
taking aspirin, but the CI was wide [11% versus 4% (95% CI 4%
fewer to 18% more)]. The risk of gastrointestinal bleeding or
wound haematoma was the same in both groups (4%).
Ticlopidine
Three RCTs compared ticlopidine 250mg twice daily versus pla-
cebo for 1 month in 339 patients undergoing AV fistula creation
[14]. By combining results, it appeared ticlopidine might reduce
AV access thrombosis, but the certainty of the evidence was low
due to risk of bias in the primary studies and serious imprecision
[three RCTs; n¼ 339; odds ratio (OR) 0.45 (95% CI 0.24–0.85);
I2¼ 20%]. There was no clear information about adverse events.
Clopidogrel
Seventy-five milligrams of clopidogrel was compared versus
placebo in two RCTs, indicating it may reduce AV fistula
thrombosis up to 6 weeks after AV fistula creation [2 RCTs;
n¼ 959; OR 0.40 (95% CI 0.13–1.19); I2¼ 54%)] [14]. The cer-
tainty of the evidence was low however, due to risk of bias in
both studies, and serious imprecision, with the CI spanning the
line of no effect. Both studies indicated a similar proportion of
bleeding events and mortality.
We identified an additional RCT including 96 participants
randomized to either clopidogrel plus a prostacyclin analogue
(epoprostenol) or placebo for 7 days before and up to 1 year after
surgery [24]. The investigators described an important improve-
ment in fistula maturation—in this study defined as a blood flow
>300mL/min or velocity >70 cm/s—for those taking dual anti-
platelet treatment (87% versus 67%), but the certainty of the evi-
dence was low due to unclear denominators. The investigators
reported no bleeds, but the external validity of the results was con-
sidered low because of stringent exclusion criteria. Only 25% of all
people set to undergo AV fistula creation were finally enrolled.
Dipyridamole and sulphinpyrazone
There were no studies assessing outcomes at 12weeks for dipyr-
idamole or sulphinpyrazone.
Anticoagulants
Warfarin or other oral anticoagulants
There were no studies assessing outcomes at 12weeks for
warfarin or other oral anticoagulants.
Perioperative anticoagulants
We identified one systematic review on systemic intra-
operative anticoagulation during AV access formation [19].
The review included three randomized trials that used systemic
heparin during AV fistula creation and found the intervention
increased AV fistula patency at 6weeks, but the quality of evi-
dence was low due to a high risk of bias in the underlying stud-
ies and large imprecision of the summary effect estimate [three
RCTs; RR 0.57 (95% CI 0.33–0.97)]. Importantly, systemic hep-
arin increased bleeding events in all access trails including an
additional RCT with both AV fistulas and grafts [four RCTs;
n¼ 411; RR 7.18 (95% CI 2.40–21.40)].
Another RCT assessed the combined use of heparin and ani-
sodamine (an anticholinergic and a1 adrenergic receptor antag-
onist used in the treatment of acute circulatory shock in China)
given immediately after AV fistula creation and found it re-
duced the risk of early thrombosis in AV fistulas compared
with placebo or heparin alone, but the study was at high risk of
bias [31].
Other
Fish oil—omega 3 polyunsaturated fatty acids
We identified a systematic review comparing fish oil versus pla-
cebo or no treatment, with content assessed as being up to date
through January 2017 [16]. In addition to two RCTs identified
by Tanner and Da Silva [14], this review included four addi-
tional RCTs assessing dosages ranging from 3 g three times
weekly to 6 g daily. Only one study assessed the effect in AV fis-
tulas and the others were in AV grafts [32]. Outcomes were
measured at 12 months; there were no data on outcomes mea-
sured within the pre-specified time period of 12weeks.
Statins
There were no studies assessing outcomes at 12 weeks for
statins.
Vonapanitase—recombinant type I pancreatic elastase
Two RCTs assessed the effect of recombinant type I pancreatic
elastase applied directly to the adventitia of the AV vessels at
the time of AV fistula creation [14]. For AV fistulas there was
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no difference in unassisted maturation at 6 weeks, regardless of
the definition of maturation. At 3 months, more AV fistulas
had matured in the group that had received vonapanitase, but a
large loss to follow-up and multiple testing issues reduced the
certainty of the evidence. Both studies listed several adverse
events including local symptoms secondary to the creation of a
new AV fistula, but according to the study authors, there were
no significant differences between placebo and recombinant
type I pancreatic elastase–treated participants.
We found an additional trial that randomized 313 people to
locally dripped vonapanitase or placebo at the time of AV fis-
tula creation. The report provided no outcome data for matura-
tion [25].
Far infrared therapy
We found one systematic review on far infrared treatment for
increasing the patency of AV fistulas, with the content assessed
as being up to date through January 2017 [18]. The review in-
cluded 21 RCTs comprising 1899 participants at the time of AV
access creation. Although not clearly reported, it appears all
studies included participants with an AV fistula. Investigators
used different techniques for delivering far infrared rays; most
commonly a device generating wavelengths between 5 and
25mm set at a height of 20 cm above the AV fistula with a treat-
ment time of 40min during each haemodialysis session. Most
studies assessed blood volume, vessel diameter or primary pa-
tency at various time points up to 1 year after fistula creation.
We awarded the review an 8 of 11 score on the AMSTAR
checklist, limited by the absence of a registered protocol,
unclear search methods and incomplete reporting of excluded
studies.
Eight studies assessed outcomes earlier than or at 3 months
after AV fistula creation, but only four could be included in the
meta-analysis.
Although the certainty of the evidence was compromised by
the small number of studies and research groups these data
were derived from, the risk of bias in the underlying studies and
the heterogeneity in the results, overall, far infrared therapy
modestly increased blood flow [three RCTs; n¼ 328; mean dif-
ference (MD) 57.2 (95% CI 9.1–105.2); I2 ¼ 93%]. In addition,
two trials comprising 180 participants showed results for AV
fistula occlusion rates. Overall, therapy with far infrared radia-
tion decreased AV fistula occlusion rates [two RCTs; n¼ 180;
RR 0.29 (95% CI 0.06–1.35); I2 ¼ 0%]. There was no evidence
of heterogeneity in these trials.
Cholecalciferol
One RCT randomized 52 participants to receive either
200 000 IU oral cholecalciferol or matching placebo [26]. High-
dose cholecalciferol had uncertain effects on AV fistula matura-
tion at 6 months [one RCT; n¼ 52; RR 0.79 (95% CI 0.45–
1.38)].
Glyceryl trinitrate
Glyceryl trinitrate was tested in a placebo-controlled clinical
trial including 200 participants [27]. An active or a placebo
patch was applied 5 cm proximal to the AV anastomosis imme-
diately after completing the surgical procedure and left in place
for 24h. The trial provided moderate-certainty evidence for no
meaningful difference in patency at 6 weeks or change in venous
diameter as a surrogate for maturation. There were no major dif-
ferences in side effects, resulting in similar numbers dropping out
in both groups, but no formal analysis was presented.
Iontophoretic intradermal injection of Salvia miltiorrhiza
We found one Chinese trial randomizing 20 participants who
had undergone radiocephalic AV fistula creation to iontopho-
retic intradermal injection (a technique that uses low-level cur-
rent to drive charged compounds across the skin) of Salvia
miltiorrhiza, a Chinese root that contains salvianolic acid B as a
potentially vasculoprotective and anti-inflammatory agent [28].
It found the experimental treatment increased the number of
successfully matured AV fistulas by 35% at 1 month [one RCT;
n¼ 20; RR 1.07 (95% CI 1.06–2.73)]. We considered the evi-
dence of low certainty because of the sample size and concerns
about changes in the primary outcome, originally to be mea-
sured at 6 months rather than 1 month.
Prednisolone
Finally, we identified a protocol for an RCT set to assess
the effect on radiocephalic AV fistula maturation of intravenous
liposomal prednisolone 150mg given twice after surgery (days
1 and 14) [29]. To the best of our knowledge, results of this
study were not yet available upon publication of the guideline.
• Translation of the evidence into recommendations
Interpreting the available data in the context of maturation is
challenging for various reasons. Most studies assessing antipla-
telet agents report on short-term vascular access thrombosis
rather than successful dialysis. This is problematic, as a reduc-
tion in AV fistula thrombosis does not necessarily translate into
improved maturation. It is true that fistula thrombosis pre-
cludes successful use of the AV access for dialysis, but if the cur-
rent treatments, predominantly aimed at reducing platelet
aggregation and coagulation, increase the risk of bleeding, a lo-
cal haematoma may cause irremediable loss of the access even
before it has ever been used. In addition, access thrombosis may
be treated using endovascular or surgical techniques and anti-
platelet agents have uncertain effects on reducing interventions
for assisting maturation.
Authors use different definitions for the concept of AV fis-
tula maturation, and that also complicates interpretation of the
data. Some investigators treat maturation as a pre-cannulation
outcome based on surrogate measures of vessel diameter
and blood flow. Whether or not an AV fistula is successfully
used for dialysis later is often ignored. The GDG judged
that an improvement in maturation using pre-cannulation
definitions would not be enough to issue a supporting
recommendation.
Lastly, many studies report primary unassisted patency after
1 year and do not distinguish between the maturation phase
and long-term patency of a matured AV fistula. As harmful
effects of treatments may change over time, differences in
primary unassisted patency may well be non-proportional too.
In other words, what benefits the maturation process may be
different from what benefits the matured AV fistula.
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The GDG felt that for a positive recommendation, interven-
tions had to improve successful use of the AV access. We
judged that in the absence of evidence for a positive effect of
successful cannulation, evidence for an effect on intermediate
outcomes such as AV access thrombosis would not be enough
to advocate treatment. But rather than formulating a neutral
statement, the group also wanted to highlight existing ambigu-
ity by communicating the items to be weighed in decision
making.
After initial recommendations were drafted, the group de-
cided to add a statement advising not to stop antiplatelet treat-
ment in adults already treated with antiplatelet agents for other
reasons. Although this chapter did not directly aim to answer
that question, it was felt that the current evidence supporting
continuation of antiplatelet treatment in adults undergoing
non-cardiac surgery would tip the uncertain benefit for matura-
tion in favour of continuing treatment [33].
Other guidelines on this topic
ESVS [34]
We suggest individualizing the indication of antiplatelet
agents to prevent thrombosis of native AV fistulas, given
that although a reduction in the risk of thrombosis was
demonstrated, the adverse effects have not been well
studied.
Grupo Espa~nol Multidisciplinar del Acceso Vascular (GEMAV)
[35]
We suggest that antiplatelet therapy for thrombosis prophy-
laxis of native AV fistula be indicated on a case-by-case basis,
because although it shows a decrease in the risk of thrombosis,
we believe that adverse effects have not been studied with suffi-
cient accuracy.
Canadian Society of Nephrology (CSN), KDIGO, National
Kidney Foundation Kidney Diseases Outcomes Quality
Initiative (NKF-KDOQI), KHA-CARI and NICE provide no
current recommendations on this topic.
Suggestions for future research
Large heterogeneity in reported trial outcomes limits
our ability to interpret the evidence correctly. Therefore
we welcome initiatives like Standardized Outcomes in
Nephrology–Hemodialysis (SONG–HD), which aim to de-
velop standardized outcomes in vascular access [4].
Implementing consensus outcomes in future trials will be the
key for improving the ability of systematic reviewers and
guideline developers to better assess the benefits and harms
of proposed treatments. Routinely collected data on vascular
outcome data in registries might be of benefit to assess strate-
gies and practices.
Most studies assess AV access thrombosis rather than AV
access maturation or the ability to perform dialysis using a
newly created AV access. In the presence of an adverse effect
that could counter the intermediate outcome, a trial including
maturation would be informative. Such a trial would likely cap-
ture other causes of maturation failure, which are currently not
taken into consideration.
CHAPTER 2 . SURGICAL AND
ENDOVASCULAR INTERVENTIONS FOR
PROMOTING AV FISTULA MATURATION
Recommendations
We suggest using regional block anaesthesia rather than
local anaesthesia for arteriovenous ﬁstula creation in
adults with end-stage kidney disease. (2C)
We suggest there is insufﬁcient evidence to support
end-of-vein to side-of-artery over side-of-vein to side-
of-artery anastomosis for arteriovenous ﬁstula creation
in adults with end-stage kidney disease. (2C)
Advice for clinical practice:
• None.
Rationale
• Background
Non-maturation is defined as a process leading to a newly cre-
ated AV access that cannot be used for haemodialysis; it does
not apply to AV grafts. Non-maturation may cause various
problems, such as a need for reintervention or for a temporary
central venous haemodialysis catheter to be inserted. An AV fis-
tula may fail because of thrombosis or because of the feeding ar-
tery or the draining vein failing to enlarge.
Physical interventions that influence these processes may re-
sult in improvement of maturation, provided their adverse
effects do not counterbalance their benefits. Such interventions
include different types of anaesthetic procedures, balloon-assis-
ted maturation, use of devices to connect the artery and the vein,
ligation of accessory draining veins, dilatation of the main drain-
ing vein or specific surgical techniques to make the anastomosis.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 2)
(Supplement 4j Search strategies—Chapter 2)
(Supplement 5j Study selection flow diagrams—Chapter 2)
(Supplement 6j Summary evidence tables—Chapter 2)
Two systematic reviews [36, 37] and 16 RCTs assessing eight
different interventions were identified [38–53]. One systematic
review and meta-analysis included six studies with 870 partici-
pants comparing the effects of regional versus local anaesthesia
on several AV fistula outcomes [36]. With respect to matura-
tion, the authors found that regional block anaesthesia pro-
duced an average 25mL/min increase in blood flow [two RCTs;
n¼ 78; MD ¼ 25.08mL/min (95% CI 19.40–30.76); I2 ¼ 53%]
and a 22% increase in primary unassisted patency [three RCTs;
n¼ 246; RR 1.22 (95% CI 1.08–1.37); I2 ¼ 45%]. Conversely,
there were no important differences for AV fistula thrombosis
and primary fistula failure. Certainty of the evidence was low and
the number of studies included in the pooled analysis was limited.
Five RCTs compared regional block anaesthesia versus local
site anaesthesia [38–42]. The first RCT included 126 partici-
pants and reported better outcomes with block anaesthesia
for primary patency at 3 months [n¼ 126; OR 3.3 (95% CI 1.4–
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7.6)] and immediate patency at the time of hospital discharge
[n¼ 126; OR 4.3 (95% CI 1.5– 15.5)] [38].
In the second RCT including 60 patients, the authors found
no meaningful differences in primary patency after brachial
plexus block or local infiltration anaesthesia [39]. They did re-
port wider diameters of the AV fistula vein and improved hae-
modynamic parameters, including blood flow at 6 months, for
brachial plexus block. However, no actual numbers and no fur-
ther details on outcome assessment were provided, thereby lim-
iting our ability to assess the certainty of these findings.
The third RCT found no differences in thrombosis, matura-
tion, time to maturation or time to first cannulation after vertical
infraclavicular block or local anaesthesia in 123 individuals under-
going creation of a first AV fistula [40]. However, the study did
not report numeric data and specific details on study design and
conduct were missing. The remaining two studies had a smaller
sample size, including 60 and 34 participants each, and described
improvements in surrogate outcomes in the group that received
regional block anaesthesia [41, 42]. The first of the two reported
improved blood flow for patients in the infraclavicular block
group but recorded similar access failures in both groups [41].
One RCT assessed whether stellate ganglion blockade with
ropivacaine given for 7 days after surgery improved outcomes
after radiocephalic fistula creation [43]. In comparison with
usual care, stellate ganglion blockade reduced the frequency of
thrombosis up to 24 h after surgery from eight to two events
(n¼ 50; denominators not reported). Time until maturation
was also shorter in the intervention group (416 7 versus
776 11 days). However, the number of participants in whom
the outcome was assessed was not reported and definitions of
maturation were variable.
A recent systematic review and meta-analysis collecting data
from seven studies and 986 participants found no differences in
AV fistula patency at 3, 6, 12 and 24months after an end-of-vein
to side-of-artery or side-of-vein to side-of-artery surgical ap-
proach [37]. The overall outcome certainty of this review was
very low due to the small number of studies included, most of
which were observational and non-randomized trials. Three
RCTs, two of which were included in the review, compared a
side-of-vein to side-of-artery anastomosis versus an end-of-vein
to side-of-artery anastomosis [44–46]. The first RCT included 71
participants and reported no difference in access patency and fis-
tula thrombosis at 3 and 9 months [44]. The second RCT en-
rolled 60 participants and found no difference in patent fistulas
at 6 months [45]. The third enrolled 336 adults and found no
meaningful differences in patency at 6 months [46].
No study addressed end-of-vein to end-of-artery anastomo-
sis or other newer techniques that are less often performed.
There were three RCTs that compared clips versus sutures in
performing an end-to-side anastomosis for AV fistula creation
[47–49]. All three found uncertain effects on primary patency
or AV fistula maturation.
One RCT compared ligation versus no ligation of the distal
vein after side-to-side anastomosis in 60 patients [50]. The
investigators reported 90% access survival at 90 days in the in-
tervention group versus 83% in the control group (P-value
(P)> 0.05). However, important aspects of study design and
conduct were not reported, making any inference problematic.
One RCT assessing the type of suture was identified [51].
The investigators compared continuous versus interrupted su-
ture of the AV fistula in 40 participants. Access survival at
2 years was found to be similar in both groups.
A small RCT comparing one-stage versus two-stage pro-
cedures for creating a brachiobasilic vein AV fistula found no
differences in primary and secondary patency or in non-
thrombotic postoperative complications [52]. Conversely,
the transposed brachiobasilic vein fistula maturation rate af-
ter one-stage procedures was lower compared with the matu-
ration rate after two-stage procedures (33% versus 100%;
P¼ 0.01), which led to premature termination of the trial.
However, serious limitations in the trial design, hamper
meaningful inference.
Finally, a small trial including 40 participants compared bal-
loon angioplasty of cephalic veins with a diameter2mm with
hydrostatic dilatation and ligation of collateral veins [53]. The
trial was considered at high risk of bias due to its small sample
size, incomplete analysis, lack of outcome definitions, omitting
of indications for interventions to prevent loss of access and
unclear blinding procedures.
• Translation of the evidence into recommendations
RCTs provided low to medium-certainty evidence overall.
However, lack of standardization in outcome reporting made
inference particularly difficult.
Five RCTs were found to provide evidence for block anaes-
thesia compared with local anaesthesia. Only one RCT was con-
sidered at low risk of bias, while the other four were considered
at high risk of bias. All studies suggested the benefit of using re-
gional block anaesthesia, but there were several considerations
that limited the strength of the recommendation to a discretion-
ary one. First, the risk of bias in these studies was generally high
and outcome data were mostly limited to surrogate outcomes.
Second, switching from local anaesthesia to regional block an-
aesthesia could unwantedly complicate the procedure, may in-
crease costs and may possibly even delay the access procedure.
Third, the main advantage of regional block anaesthesia was felt
to be vein dilation, which could also be achieved by other
means, such as creating warm conditions.
For the comparison of end-of-artery to side-of-vein versus
side-to-side anastomosis, there were two reports, which were
considered at medium risk of bias, with available results insuffi-
cient to recommend one type of anastomosis over another but
equally insufficient to indicate equipoise between the two.
Three reports were available on the comparison of clips ver-
sus sutures for AV fistula creation. Sample sizes were small and
the studies had important shortcomings, leaving important un-
certainty as to the benefit of one technique over the other.
Considering this uncertainty, the GDG felt that technique
choice should be left to the surgical team based on experience
and personal preference. It was felt any recommendation would
confuse the end user rather than clarify any ambiguity, such
that no recommendation was formulated.
The guideline group considered the other trials to be prelim-
inary at best, providing a limited basis for formulating a recom-
mendation in either direction. Hence they decided to refrain
from making statements related to vein ligation, suture
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technique, angioplasty or techniques for creating a brachioba-
silic AV fistula.
Other guidelines on this topic
ESVS [34]
Regional anaesthesia should be considered in preference to
local anaesthesia for vascular access surgery because of a possi-
ble improvement in access patency rate..
The CSN, GEMAV, KDIGO, NKF-KDOQI, KHA-CARI and
NICE provide no current recommendations on this topic.
Suggestions for future research
The available reports do not resolve the uncertainty about
long-term effects and only do so incompletely with regards to
side effects. New multicentre trials comparing regional block
anaesthesia with other anaesthetic techniques would help
strengthen the evidence base. Larger trials comparing different
anastomotic techniques are also advocated. Standardization of
outcomes and estimation of adequate sample sizes are needed.
CHAPTER 3. SURGICAL AND
ENDOVASCULAR INTERVENTIONS FOR
NON-MATURING AV FISTULAS
Recommendations
We suggest there is insufﬁcient evidence to support open
surgical over endovascular interventions as the preferred
treatment for non-maturing arteriovenous ﬁstulas in
adults with end-stage kidney disease. (2D)
Advice for clinical practice:
• Decisions on how to treat non-maturing AV ﬁstulas are likely
best based on local resources, experience and success rates.
• Institutions likely beneﬁt from building a dedicated multi-
disciplinary vascular access team with clinical experience in
various techniques available for non-maturing AV ﬁstulas.
Rationale
• Background
To allow successful use of a newly created AV fistula, the out-
flow vein needs to enlarge sufficiently to allow insertion of one
or two needles and sustain the blood flow required for adequate
dialysis. Unfortunately, up to a quarter of newly constructed
AV fistulas fail to mature [54]. The outflow vein may not en-
large for many reasons, some of which can be remedied by sur-
gical or radiological endovascular interventions. If unsuccessful,
however, then such treatments may reduce quality of life by in-
creasing the number of interventions, increase workload and in-
flate costs. This may also delay creation of an alternative
permanent AV access.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 3)
(Supplement 4j Search strategies—Chapter 3)
(Supplement 5j Study selection flow diagrams—Chapter 3)
(Supplement 6j Summary evidence tables—Chapter 3)
No RCTs were identified comparing the benefits or harms of
surgical or radiological endovascular interventions versus one
another or versus no treatment.
A recent narrative review that included an attempt at com-
prehensively searching multiple databases found 28 non-ran-
domized uncontrolled studies recording clinical success, 1-year
primary patency or 1-year secondary patency of various surgi-
cal and radiological endovascular techniques (Table 5 and 6)
[54].
Thirteen studies used balloon angioplasty, defined as any
technique, whereby a catheter is inserted in the AV fistula to di-
late a stenotic vessel, mostly at the juxta-anastomotic or the
draining vein. It led to clinical success in 43–97% of procedures,
with 1-year primary unassisted patency of 28–72% and 1-year
secondary patency of 68–97%. Rupture of the venous wall oc-
curred in 15% of cases, the majority of which could be man-
aged with prolonged balloon inflation. In two studies, clinicians
dilated diseased radial arteries feeding a radiocephalic AV fis-
tula, which resulted in 1-year primary unassisted patency of 65
and 83% and 1-year secondary patency of 86 and 96%. Balloon-
assisted maturation is a technique whereby the vein of an AV
fistula is subjected to staged, serial, long-segment balloon angio-
plasty dilations (e.g. every 2 weeks) until it reaches the desired
diameter and flow rate. It was investigated in four studies and
was considered clinically successful in 55–89% of interventions,
but none of the studies provided data for 1-year primary unas-
sisted or secondary patency. Adverse effects, including local
Table 5. Summary of case series assessing the effect of radiological endovascular interventions for non-maturing AV ﬁstulas
Technique Target lesion No. of
studies
No. of
patients
Clinical
success
(range) (%)
1-year
primary
patency (%)
1-year
secondary
patency (%)
Balloon angioplasty Stenosis in draining vein or
juxta-anastomotic region
14 657 43–97 28–72 68–97
Balloon angioplasty Stenosis in arterial inﬂow 2 99 91–98 65–83 86–96
Balloon-assisted maturation Non-dilating veins 4 156 55–89 – –
Endovascular accessory vein obliteration – 1 34 65 – –
Balloon angioplasty þ endovascular
accessory vein obliteration
Stenosis in draining vein or
juxta-anastomotic region
6 538 78–92 62 68–94
Balloon angioplastyþ stent deployment Long segment stenosis in
draining vein
1 12 100 65 72
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bleeding, rupture and thrombosis, occurred frequently (>40%
of procedures) [55]. Endovascular accessory vein obliteration is
a procedure whereby a metal coil is inserted in a collateral com-
peting vessel to increase blood flow through the AV fistula. It
can be performed as an isolated intervention or in addition to
balloon angioplasty, with variable results. Finally, balloon an-
gioplasty has been conducted in combination with stent deploy-
ment in cases of stenosis of long venous segments with
moderate 1-year primary and secondary patency (65 and 72%,
respectively).
Surgical intervention usually involves (i) proximal AV neo-
anastomosis, defined as any technique, whereby a new connec-
tion is created between the inflow artery and outflow vein; (ii)
accessory vein ligation, defined as any procedure whereby col-
lateral competing vessels are tied to increase blood flow through
the AV fistula; or (iii) a combination of both. One-year patency
in uncontrolled studies varies from 68 to 78% for primary pa-
tency and from 85 to 95% for secondary patency. Several other
techniques for aiding AV fistulas that are failing to mature have
been experimented with during the last 5 years, including radial
artery deviation and reimplantation or placement of an internal
or external anastomotic device. Individual studies are small and
obtained success rates of similar magnitude to other surgical
interventions.
A small retrospective study including 46 participants com-
pared surgical proximal neo-anastomosis with endovascular in-
tervention [56]. The group that had undergone surgical
intervention had a cumulative AV fistula survival of 83% com-
pared with 43% for those who had undergone an endovascular
treatment. However, effect estimates were not adjusted for base-
line patient and vessel characteristics. A second retrospective
study that compared surgical proximal neo-anastomosis versus
balloon angioplasty found similar results, with primary patency
of 71% in the group treated with surgery versus 41% in the
group treated with balloon angioplasty [57]. However, results
for secondary patency were of similar magnitude and, again,
results were not adjusted for baseline differences between the
study groups. There was no information on the number of
reinterventions.
• Translation of the evidence into statements
Several surgical and endovascular interventions are available to
help non-maturing AV fistulas reach a stage where they can be
used successfully for haemodialysis. Both surgical and endovas-
cular procedures achieve moderate primary patency and rather
good secondary patency at 1 year. The variability in outcome
for both categories is large, probably due to differences in the
study population, and perhaps also due to differences in exper-
tise of the vascular access team. The trade-offs from aggressive
efforts to maximize AV fistula maturation may be prolonged
catheter use, as creation of an alternative permanent vascular
access is delayed. Multiple reinterventions may be taxing for
patients and ultimately reduce quality of life in comparison
with rapid creation of an alternative access or even permanent
catheter use. Many of these questions remain unanswered to
date.
Also, data are limited to primary and secondary patency at 1
year and seldom provide insight into true longevity of the AV
access. AV fistulas that require intervention before maturation
have shorter secondary patency duration than those that ma-
ture without an intervention [58]. The cumulative AV fistula
survival is markedly inferior in patients requiring two or more
interventions to achieve maturation as compared with those re-
quiring one or no intervention. In addition, AV fistulas requir-
ing more than one intervention to achieve maturation need
more interventions to maintain long-term patency once hae-
modialysis using that AV fistula is started [56].
Comparative studies between surgical and endovascular
interventions are scarce, retrospective and uncontrolled for
some of the baseline characteristics that may influence both the
choice of procedure and outcome. With the data currently at
hand, the guideline group felt the available evidence to be insuf-
ficient to suggest one approach over another.
It seems reasonable to assume that clinical multidisciplinary
expertise in the absence of clear guidance may be evenmore im-
portant than it is for other areas. Building and nurturing a team
of dedicated vascular access specialists may be what maximizes
success. It allows team members to gain experience in the vari-
ous techniques available and to monitor success as well as com-
plications at a local level. In the absence of clear evidence that
favours one intervention over another, or even comparative
studies assessing the trade-offs and harms associated with inter-
ventions to aid the non-maturing fistula, at least having a struc-
tured approach may benefit outcomes.
Other guidelines on this topic
GEMAV [35]
We recommend a clinical check-up be performed at 4–
6weeks after creation to definitively detect a delay in or absence
of AV fistula maturation from its creation to this moment and
elective treatment proposed. We recommend confirming the
suspected lack of maturation by Doppler ultrasound.
Table 6. Summary of case series assessing the effect of surgical interventions for non-maturing AV ﬁstulas
Technique Target lesion No. of
studies
No. of
patients
Clinical
success
(range) (%)
1-year
primary
patency (%)
1-year
secondary
patency
(%)
Proximal neo-anastomosis Stenosis in juxta-anastomotic region 2 71 90 71–78 87–95
Accessory vein ligation – 3 66 82–89 – 75
Proximal neo-anastomosis þ
accessory vein ligation
Stenosis in juxta-anastomotic region 2 62 87–94 68 85–86
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We suggest early treatment of the non-matured native AV fis-
tula to favourmaturation and to prevent thrombosis and definitive
loss. We recommend percutaneous or surgical techniques not be
used systematically to promotematuration of native AV fistulas.
We suggest surgery as the first treatment option (proximal
reanastomosis) in native AV fistulas with maturation failure as-
sociated with juxta-anastomotic stenosis. In cases where this is
not possible, endovascular treatment (percutaneous angio-
plasty) should be proposed.
We suggest significant accessory veins associated with matu-
ration failure be disconnected by percutaneous ligation, surgical
ligation or endovascular embolization with coils. We suggest
endovascular treatment be used in the presence of stenosis and
surgical treatment when there is no stenosis as the first option,
given the lower complexity and health care costs.
We recommend angioplasty in cases of non-matured native
AV fistulas with proximal venous stenosis.
We suggest angioplasty of the arterial stenosis when this is
the cause of non-maturation of the AV fistula in cases in which
the vascularization of the limb is not compromised.
The CSN, ESVS, KDIGO, NKF-KDOQI, KHA-CARI and
NICE provide no current recommendations on this topic.
Suggestions for future research
Given the absence of comparative data, a randomized trial com-
paring surgical versus radiological endovascular interventions
would be informative. Investigators should assess long-term out-
comes and record the timing, type and incidence of interventions
required to achieve both maturation and long-term access pa-
tency. Only centres experienced in both options should partici-
pate. Careful reporting of adverse events and patient quality of
life will be instrumental to inform future guidance in this field.
CHAPTER 4. SELF-ADMINISTERED
INTERVENTIONS FOR AV FISTULA
MATURATION
Recommendations
We suggest that a standardized exercise programme involv-
ing hand and arm exercises may improve arteriovenous ﬁs-
tula maturation in adults with end-stage kidney disease. (2C)
There is insufﬁcient evidence to support speciﬁc exercise
programmes or physical interventions to promote arte-
riovenous ﬁstula maturation in adults with end-stage
kidney disease. (-D)
Advice for clinical practice:
• Involving patients more actively in preparing for haemo-
dialysis may improve self-management skills and health
literacy and thereby well-being.
Rationale
• Background
Successful maturation of a newly created AV fistula is essential
to allow its use for adequate haemodialysis. Unfortunately the
newly created AV fistula fails to mature in up to a quarter of
cases, leading to additional invasive procedures and reduced
quality of life. Interventions that ensure improved maturation
would surely be welcomed by all. Simple interventions that can
be performed by patients themselves, including hand exercises
and self-surveillance, seem attractive, presuming they would
cause fewer adverse events than medical or surgical interven-
tions. Past guidance suggested performing isometric hand exer-
cise before and following creation of the AV fistula, as it was
thought to increase blood flow and, therefore, enlarge vein di-
ameter [59]. The evidence base supporting these recommenda-
tions was patchy and required updating.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 4)
(Supplement 4j Search strategies—Chapter 4)
(Supplement 5j Study selection flow diagrams—Chapter 4)
(Supplement 6j Summary evidence tables—Chapter 4)
We identified three RCTs involving hand or other exercises
to enhance maturation of newly created AV fistulas [60–62]
and one RCT assessing a device developed to apply reliable in-
termittent pneumatic compression to the outflow veins [63].
We found no RCTs assessing other forms of patient educa-
tion, patient behaviour or self-monitoring.
The first RCT compared simple exercises with opening and
closing of fingers versus a structured exercise programme that
included squeezing a tennis ball and exercising with a dumbbell
and flex-band with a tourniquet positioned proximal to the AV
fistula. In the per protocol analysis of 25 participants in both
groups, 17 patients performing the simple exercises and 22 fol-
lowing the structured programme had matured fistulas 2 weeks
after creation (P¼ 0.14) [60]. The study was considered at high
risk of bias because of subjective outcome definition and inade-
quate random sequence generation.
The second RCT included 18 participants and compared
the use of a handgrip versus a soft ball for hand-squeezing exer-
cises. This study only reported surrogate outcomes such as the
increase in vein diameter before and after exercising. The num-
ber of matured fistulas overall and within each group were not
reported [61]. The trial was considered at high risk of bias be-
cause of selective outcome reporting and lack of information on
important elements in the design and conduct of the study.
The third RCT included 72 participants who were random-
ized after proximal or distal AV fistula creation to either a struc-
tured programme, which consisted of repeated flexion and
extension of the elbow and wrist in addition to opening and
closing of the hand, or usual lifestyle without specific exercises
[62]. After 1 month there were more people with a clinically
mature AV fistula in the group that had exercised than in the
group that had not (95% versus 81%; P¼ 0.07). Also, more AV
fistulas were considered ultrasonographically mature among
the people who had exercised than among those who had not
(82% versus 74%; P¼ 0.45). Importantly though, results were
not statistically significant and maturation definitions were
based on clinical and radiological criteria rather than on suc-
cessful dialysis. In addition, although an attempt was made to
adequately randomize the participants due to sample size
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restrictions, important imbalances existed between the groups
that could have biased the results. In particular, there were
fewer diabetic patients with peripheral vascular disease in the
intervention group.
A final RCT assessed a new device developed to apply reliable
intermittent pneumatic compression to the outflow veins [63].
The device consists of a miniaturized control unit attached to a
wearable pneumatic cuff that inflates to a pressure of 60mmHg,
held for 20 s, and subsequently deflates to 10mmHg for 55 s be-
fore the cycle repeats. Forty-eight participants were randomized
to either the real or a sham device 1 week after successful AV fis-
tula creation and were asked to wear the device 6 h a day for 4
weeks. After 1 month there was a statistically significant 20%
greater increase in venous diameter 5 cm proximal to the AV
anastomosis for the participants in the experimental group. At
10 cm, the average difference was 7% and was no longer statisti-
cally significant and at 15 cm there was no difference between the
groups. There was no information on maturation. There were no
important adverse events reported in the experimental group.
• Translation of the evidence into recommendations
We found two RCTs, both comparing different self-
administered hand exercises. Neither indicated one intervention
to be superior over another, but data were sparse and the studies
were at high risk of bias. In addition, we found one RCT compar-
ing a structured exercise programme versus no exercises, which
provided some evidence that such a programme may be benefi-
cial. We found this evidence to be of low certainty due to the risk
of selection bias and wide CIs from sample size restrictions. More
importantly, outcome measures were of a surrogate nature, using
clinical and ultrasonographic criteria-based maturation rather
than successful dialysis. One month may be too soon to assess the
finality of a maturation process and data might have been differ-
ent if the AV fistulas had been reassessed 2 weeks later.
The GDG felt it would be unlikely that simple exercises,
such as hand squeezing, could have any harmful outcomes,
provided that the patients waited until sufficient wound heal-
ing had occurred. Indeed, the no-exercise controlled trial did
not report any important adverse events. Despite the study
limitations, the GDG felt there was some indication that a
structured exercise programme could be useful, and would
not represent important resource implications, such that in
the absence of important adverse events they supported the
use of such programmes in the postoperative phase of AV fis-
tula creation.
There was one trial testing a newpneumatic device, but the results
were considered preliminary and outcomes surrogate in nature.
Other guidelines on this topic
ESVS [34]
Structured postoperative hand exercise programmes should
be considered to increase AV fistula maturation. (IIa-B)
NKF-KDOQI [59]
Fistula hand–arm exercise should be performed. (B)
GEMAV [35]
We suggest that the patients do exercises before and after the
creation of native AV fistulas to promote maturation.
The CSN, KDIGO, KHA-CARI and NICE provide no current
recommendations on this topic.
Suggestions for future research
Given the scarcity of evidence on self-administered interven-
tions to promote maturation, randomized trials comparing var-
ious exercise programmes versus no exercise with adequate
sample sizes and standardized outcomes would be informative
for future recommendations in this field.
CHAPTER 5 . PERIOPERATIVE
PROPHYLACTIC ANTIBIOTICS FOR
PREVENTING AV ACCESS INFECTION
Recommendations
We recommend giving preoperative antibiotic prophylaxis
for arteriovenous graft insertion in adults with end-stage
kidney disease. (1C)
We suggest giving preoperative antibiotic prophylaxis for
complex arteriovenous access procedures in adults with
end-stage kidney disease. (2D)
We suggest not giving preoperative antibiotic prophy-
laxis for simple arteriovenous access procedures in
adults with end-stage kidney disease. (2D)
Advice for clinical practice:
• Simple AV access procedures include the creation of a na-
tive radiocephalic or native brachiocephalic AV ﬁstula.
• Complex AV access procedures include those that are not
considered simple.
Rationale
• Background
Creation of an AV access for haemodialysis can be considered a
clean surgical procedure. Accordingly, preoperative antibiotics
should not be necessary and overuse may induce bacterial resis-
tance. However, patients with ESKD have impaired immunity
with an increased risk of infection. In addition, the risk and
consequences may be dependent on the type of AV access pro-
cedure. If prosthetic material is inserted and becomes infected
during surgery, then the newly created AV access may be jeop-
ardized. As such, recommendations for antibiotic prophylaxis
may be different for AV fistula and AV graft procedures and
must balance benefits and harms appropriately.
• Summary of the evidence
(Supplement 3j Review questions—PICO Format—Chapter 5)
(Supplement 4j Search strategies—Chapter 5)
(Supplement 5j Study selection flow diagrams—Chapter 5)
(Supplement 6j Summary evidence tables—Chapter 5)
We identified two RCTs assessing perioperative antibiotics
for AV graft insertion [64, 65]. No studies were found that
assessed prophylactic antibiotics for AV fistula creation.
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The first RCT included 38 participants who were random-
ized to either cefamandole or placebo before insertion of an AV
graft in the radiocephalic (n¼ 19) or femorosaphenous
(n¼ 19) position [64]. Cefamandole or placebo was given intra-
venously 30min prior to surgery and 6–12 h postoperatively.
The overall infection rate was 26%. Two of 19 participants
treated with antibiotics and 8 of 19 participants given placebo
developed an infection (RD ¼ 0.32; P< 0.04). The study was
considered at unclear risk of bias for not reporting the randomi-
zation procedure.
The second RCT included 206 patients who underwent a to-
tal of 408 procedures to create a permanent vascular access [65].
Patients were randomized to either a single intravenous dose of
750mg of vancomycin6–12h before the vascular access place-
ment procedure (206 procedures) or to no prophylactic antibiot-
ics (202 procedures). Within 30 days, and before using the AV
access for chronic dialysis, infection developed twice in the anti-
biotics group and 12 times in the group that had not received an-
tibiotic prophylaxis (RD ¼ 0.05; P< 0.01). All 14 infections
occurred in upper limb polytetrafluoroethylene (PTFE) grafts.
The study was considered at high risk of selection bias as the al-
location was based on the hospital record number.
• Translation of the evidence into recommendations
There are no randomized trial data on perioperative antibiotic
prophylaxis for AV fistula creation. The GDG felt that in the
absence of direct evidence they should rely on extrapolation of
evidence for antibiotic prophylaxis for preventing surgical site
infections in general. They drew on an evidence review con-
ducted by NICE in January 2017 [66]. The review process found
evidence supporting antibiotic prophylaxis to patients before
clean surgery involving the placement of a prosthesis or im-
plant; this was based predominantly on the evidence for a clini-
cally relevant reduction in surgical site infections for this
category. There is far less evidence related to clean and simple
procedures, a single randomized trial indicating evidence for no
effect. Our GDG considered the creation of a native fistula to be
a ‘clean’ and short surgical procedure in a non-
contaminated area. Hence they judged antibiotic prophylaxis
non-mandatory in this setting.
In cases where prosthetic materials are used, two RCTs pro-
vided low-certainty evidence for a clinically relevant reduction
in surgical site infections. This is in line with the conclusion
from the evidence review conducted for the NICE guideline
[66]. We found no evidence for preferring one type
of antibiotic over another in this setting. The GDG judged both
first-generation cephalosporins as well as vancomycin, or teico-
planin could be considered, depending on the local practice and
epidemiology of methicillin resistance.
Other guidelines on this topic
ESVS [34]
We recommend that broad-spectrum antibiotics should be
given prior to the insertion of an AV graft, including prophy-
laxis for Staphylococcus aureus. (IA)
In carriers or in units with a high incidence of methicillin-
resistant S. aureus, the administration of a parenteral glycopep-
tide is recommended. (IB)
GEMAV [35]
Due to the risk of infection associated with the prosthetic
AV fistula, we recommend the use of perioperative prophylactic
antibiotics.
The CSN, KDIGO, NKF-KDOQI, KHA-CARI and NICE pro-
vide no current recommendations on this topic.
Suggestions for future research
An adequately powered RCT comparing routine administra-
tion of antibiotics versus no antibiotic prophylaxis before the
creation of native AV fistulas would be helpful to resolve the
remaining uncertainty.
CHAPTER 6 . TIMING OF FIRST
CANNULATION
Recommendations
AV fistulas
In adults requiring haemodialysis, we suggest arteriove-
nous ﬁstulas can be cannulated 4 weeks after creation if
they are considered suitable for cannulation on clinical
examination. (2C)
In adults requiring haemodialysis, we recommend
against cannulating arteriovenous ﬁstulas sooner than 2
weeks after their creation. (1B)
In adults requiring haemodialysis, we suggest against
cannulating arteriovenous ﬁstulas 2–4 weeks after their
creation unless this will avoid placement of a central ve-
nous catheter for haemodialysis. (2C)
AV grafts
In adults requiring haemodialysis, we recommend ‘early
cannulation type’ arteriovenous grafts can be cannulated
as soon as wound healing permits. (1B)
In adults requiring haemodialysis, we suggest against
cannulating a ‘standard type’ arteriovenous graft sooner
than 2 weeks after insertion unless this will avoid place-
ment of a central venous catheter for haemodialysis. (2B)
Advice for clinical practice:
• In practice, suitability for cannulation on clinical exami-
nation is determined by the presence of a palpable vein
and good thrill.
• If clinical examination is inconclusive, ultrasound with ﬂow
measurement may help in deciding whether to cannulate.
• Bedside ultrasound-guided cannulation may be helpful in
avoiding complications and decreasing the number of
failed cannulations.
• Using single-needle dialysis, low dialysis blood ﬂows and
smaller needles (17 gauge) may prevent harm to AV ﬁstu-
las that are cannulated early.
• Wound healing refers to the tissue around the body of the
graft rather than the incision site.
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Rationale
• Background
It has been standard practice to avoid cannulating an AV fistula
during the first 6 weeks after its creation. For standard PTFE
AV grafts, this period has always been 2 weeks, but new-genera-
tion grafts have been marketed for their early cannulation prop-
erties, allowing use as an alternative to central venous catheters
for prompt access [67]. On the one hand, cannulating a newly
created vascular access too early may result in perforation, hae-
matoma or even destruction of the access site. On the other
hand, waiting may cause needless insertion of haemodialysis
catheters and lead to delays in searching for causes of non-
maturation or in creating an alternative AV access.
We wanted to assess when the different AV access types may
be reasonably cannulated successfully and whether certain eas-
ily measured variables indicate the first attempt at cannulation
is likely to be successful. These variables included clinical obser-
vations and ultrasound-based measurements such as vessel di-
ameter, blood flow, wall thickness and depth of the AV access.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 6)
(Supplement 4j Search strategies—Chapter 6)
(Supplement 5j Study selection flow diagrams—Chapter 6)
(Supplement 6j Summary evidence tables—Chapter 6)
AV fistulas
We found no RCTs assessing the effect of the timing of first
cannulation on outcome in AV fistulas.
Eight observational studies assessed the effect of the time
point of first cannulation after AV fistula creation on outcome
[68–75] and the results were conflicting.
Two studies based on the Dialysis Outcomes Practice Patterns
Study (DOPPS) provided centre-level information on the timing
of first cannulation [68, 69]. When analysing all patients who
started haemodialysis with an AV fistula (n¼ 894), the median
time to first cannulation varied greatly between countries, averag-
ing 25 days for Japan, 27 days for Italy, 42 days for Germany, 80
days for Spain, 86 days France, 96 days for the UK and 98 days
for the USA [68]. No association was found between cannulating
sooner versus later than 28days after AV fistula creation and age,
sex and 15 different classes of variables reflecting comorbidity.
Cannulating an AV fistula sooner than 14days after its creation
was associated with a 2-fold increased risk of subsequent fistula
failure versus cannulating after 14 days (P< 0.01). There was no
difference for AV fistulas cannulated within 15–28days com-
pared with fistulas cannulated within 43–84days.
Based on the same cohort, investigators analysed the influence
of time to first cannulation and blood flow rate at first cannula-
tion on primary fistula failure [69]. For newly created AV fistulas,
the first attempt at cannulation occurred within 2 months after
placement in 36% of US, 79% of European and 98% of Japanese
facilities. There was no indication that centres that cannulated
their AV fistulas within 4 weeks after creation had higher risks of
later fistula failure. The facility median blood flow rate was not
significantly associated with access failure either.
A retrospective study including 190 Moroccan haemodialy-
sis patients found no difference in the risk of fistula thrombosis
whether cannulation occurred before or after 21 days following
AV fistula creation [70]. However, the authors did not provide
numeric data, there was no attempt at adjusting for confound-
ers and it was unclear when or how outcomes were measured.
A prospective cohort study enrolled 118 people with a newly
created AV fistula [71]. In contrast to the DOPPS data, post-
poning cannulation until 1 month after fistula creation reduced
the risk of thrombosis by 60% [RR 0.40 (95% CI 0.19–0.84)].
This finding was supported by a second prospective cohort in-
cluding 535 people with newly created AV fistulas [72]. In this
study, which adequately controlled for possible confounders,
cannulating AV fistulas within 30 days of their creation was as-
sociated with twice the hazard for primary AV fistula failure.
Two studies published by a group from the UK retrospectively
reviewed fistula patency in 1167 fistulas created between 2002 and
2015 with different cut-off points to define early cannulation [73,
74]. Both analyses were unadjusted comparisons using the AV fis-
tula as the unit of analysis rather than the individual patient. The
first report used a cut-off of 30days after fistula creation to define
early and late cannulation and found no difference in fistula fail-
ure within 90days following first cannulation between the two
groups (P¼ 0.35) [73]. The second report separately analysed AV
fistula survival in pre-dialysis patients and patients on mainte-
nance haemodialysis with a definition of early cannulation as an
attempt that happened within 4 weeks after fistula creation. It
found no difference in fistula survival between the cohorts [74].
One study prospectively included all adults with CKD set to
undergo upper extremity AV fistula creation at one of seven US
centres to assess the association between a variety of clinical pro-
cesses, cannulation and successful haemodialysis [75]. In a subset al-
ready treated with chronic haemodialysis at the time of AV fistula
creation, the investigators analysed the influence of timing to first
cannulation on overall maturation, broadly defined as successful di-
alysis during a 4-week period. They found that for every month a
first cannulation attempt was delayed beyond 2 months, the odds
for successful dialysis gradually diminished [OR 0.93 (95% CI 0.89–
0.98)]. The certainty of the evidence was affected by possible resid-
ual confounding and inflated type 1 error frommultiple analyses.
Four studies assessed the value of clinical assessment or
ultrasound-based measures in determining readiness for first
cannulation [76–79].
The first study assessed whether ultrasound and clinical eval-
uation of AV fistulas at 4 weeks after creation predicted future suc-
cessful cannulation [76]. Clinical appreciation, by experienced
nurses unaware of the ultrasound findings, consisted of examining
the flow characteristics (categorized as thrill/pulse/audible bruit
with or without a palpable thrill), the vein calibre and the straight-
ness and depth of the vein. Clinical appreciation, a vein diameter
>5mm and arterial end diastolic velocity>110cm/s had a positive
predictive value for successful cannulation of 81, 90 and 87%, re-
spectively. The negative predictive value, however, was only 63, 53
and 37%, respectively. Importantly, this study excluded patients
with AV fistulas that had already thrombosed prior to or at 4 weeks.
A second, single-centre consecutive cohort of 20 patients
assessed whether venous wall thickness and circumferential
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stress could predict successful cannulation, defined as successful
dialysis without substantial extravasation of blood at the cannu-
lation site [77]. The investigators used very high frequency–
based assessment (55MHz probe) of intima-media thickness,
defined as the sum of a thin blood–intimal interface and a uni-
form hypoechogenic media. A minimum threshold intima-me-
dia thickness of 0.13mm was associated with successful
cannulation without extravasation (sensitivity 87%, specificity
92%). Importantly, patients were only cannulated if the venous
diameter was >6mm, the blood flow >600mL/min and the
depth of the fistula <6mm for a segment >6 cm 6 weeks after
AV fistula creation.
A third cohort study retrospectively assessed the maturation
surveillance ultrasound examinations of 69 patients performed
within 4 months of AV fistula creation [78]. A venous diameter
>0.4 cm or a blood flow>500mL/min were reasonable predic-
tors of successful cannulation within 4 months. In patients who
met both criteria, cannulation was successful in 19 of 20, while
in those who failed both criteria, successful cannulation oc-
curred in only 5 of 15. In this study, clinical assessment by expe-
rienced nurses correctly predicted successful cannulation in 24
of 30 patients (accuracy of 80%).
Finally, a fourth study recorded fistula flow and diameter for
12weeks following creation of the AV fistula. None of 14 fistu-
las with a diameter increase<0.4 cm 14days after creation ma-
tured, while all 38 fistulas with a diameter increase >0.4 cm
were successfully cannulated within 12weeks. The same results
were seen with a cut-off blood flow <400 or >400mL/min
[79].
AV grafts
We found one RCT comparing cannulation within 1–2 days
versus 10–14 days after insertion of an upper limb standard
PTFE AV graft in 36 patients requiring semi-urgent dialysis.
There were no meaningful differences in the number of par-
ticipants with haematomas, thrombosis or infection. There
was no meaningful difference in compression time to control
bleeding or venous back pressure. Evidence was considered
moderate to low certainty because of unclear risk of bias and
wide CIs [80].
We found an additional six observational studies covering
AV grafts [69, 70, 81–84]. All directly assessed the effect of the
time point of first cannulation after AV graft creation on out-
come: four in prospective [69, 71, 83, 84] and 2 in retrospective
cohort studies [81, 82].
Two prospective cohort studies reported on cannulation
within the first 3 days after creation [83, 84]. The first study
assessed 76 stretch-expanded PTFE grafts and found no mean-
ingful difference in primary patency after 3 and 12months for
those cannulated after 1–2 days versus those cannulated after 2
weeks [84]. The second study from the USA reported an unad-
justed comparison of early cannulation within 72 h of graft
placement to late cannulation >21 days following graft place-
ment in 87 patients, using a multilayer graft designed for early
cannulation. They found no meaningful difference in cumula-
tive graft patency rates up to 12months of follow-up (76% ver-
sus 77.5%; P¼ 0.7) [83].
Three studies reported on cannulation of standard AV grafts
within 14 days and compared the results with AV grafts cannu-
lated after 14 days [69, 81, 82].
In the DOPPS, the first cannulation of AV grafts typically
occurred within 2–4 weeks at 62% of US, 61% of European and
42% of Japanese facilities [69]. In 17% of US, 16% of European
and 42% of Japanese facilities that cannulate their AV graft
within 2 weeks of creation, overall risk of AV graft failure, de-
fined as the time to first thrombosis or access salvage procedure,
did not differ from those cannulating at later times.
A retrospective study reported on the 12-month failure of 64
AV grafts in 58 people who had their standard AV graft’s first
cannulation at different times after insertion, starting from the
second week after surgery. The study results suggested that the
timing of the first cannulation of a standard AV graft had no
significant impact on graft survival [81]. The overall incidence
of primary AV graft failure, defined as the first occurrence of
graft thrombosis or need of any invasive access procedure, and
of cumulative graft failure, defined as irreparable loss of the
graft, at 12months was 72 and 41%, respectively. There was no
association between the time of first cannulation and cumula-
tive graft loss. Primary graft failure seemed to decrease as the in-
terval between the procedure and the first cannulation
increased, but results were not statistically significant and the
certainty of the evidence was very low due to the requirement of
successful first cannulation as an inclusion criterion and censor-
ing for patient mortality (15% grafts), disproportionally present
in the later time groups. A third and retrospective study in 270
people receiving a standard AV graft found secondary patency
rates up to 15% lower in grafts cannulated within versus after
14 days. The certainty of the evidence was very low, as we con-
sidered the study at high risk of bias, with comparisons of raw
numbers not adjusted for confounders [82].
Finally, a prospective cohort in North America enrolling 147
people with AV grafts found first cannulation after versus
within 1 month had uncertain effects on the risk of thrombosis
within 1 year of cannulation [n¼ 147; RR 0.77 (95% CI 0.43–
1.38)]. The analysis had been adequately adjusted for the main
confounding factors [71].
• Translation of the evidence into recommendations
Several observational studies consistently indicate that cannu-
lating an AV fistula within 14 days of its creation increases—al-
most doubles—the risk of unsuccessful dialysis and/or later AV
fistula failure compared with cannulating an AV fistula after
14 days. The evidence for waiting another 14 days is less impres-
sive and not consistent. In addition, the negative effects of a fur-
ther delay, that is, the need for urgent central venous catheter
placement, have never been studied and may counterbalance
the positive effects of fistula longevity. In the absence of this evi-
dence, the GDG felt that in this case, avoiding placement of a
catheter weighed more heavily and by allowing another 14 days
for further maturation weighed less in comparison with the pre-
vious case. In the absence of the need for urgent dialysis, it
seems reasonable to allow for an additional 14 days of further
maturation before attempting to cannulate the AV fistula. This
also holds true for those already receiving dialysis via a tun-
nelled catheter unless a problem with the catheter should arise.
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AV fistulas with a palpable vein and good thrill at 4 weeks
after their creation can be cannulated successfully in most
cases. In this situation, additional ultrasound measures are
unlikely to be helpful. However, in the absence of such a thrill,
there is low-quality evidence in line with clinical practice sug-
gesting that an AV fistula diameter >4–5mm or a blood flow
>500mL/min indicates the fistula has matured and can be can-
nulated successfully. In the absence of a thrill, a diameter
<4mm and a blood flow <400mL/min make it highly suspi-
cious that the AV fistula will fail without intervention. Although
other techniques to assess AV fistula characteristics have been
proposed, further study is needed to assess their added value.
One small RCT and several observational studies provide
moderate-certainty evidence that cannulating an AV graft
within 2 days of its insertion has no negative consequences for
short- or long-term AV graft outcome, including infection
rates. This is the case even with standard PTFE grafts. There
does not seem to be an increase in the complication rate, but
early cannulation of standard PTFE grafts has never found its
way into routine practice around the world. RCTs of the new
grafts designed for early cannulation are not available. One ret-
rospective study showed no increase in complications when
cannulation of an early cannulation graft within the first 72 h
was compared with cannulation after 3weeks. How this influ-
ences the added benefit of avoiding temporary and tunnelled
central venous catheter placement is unclear, but it can only be
expected to further tip the benefit–harm balance in favour of
supporting early cannulation when necessary.
Other guidelines on this topic
ESVS [34]
AV fistulas should be considered for cannulation 4–6weeks
after creation and standard AV grafts after 2–4weeks. (IIa-B)
AV fistula cannulation before 2weeks should generally not
be done. (III-C)
AV fistula cannulation 2–4weeks after creation may be con-
sidered in selected patients under close supervision. (IIIb-B)
GEMAV [35]
We recommend that cannulation of the native AV fistula
not be initiated in the first 2 weeks following creation and that
the optimal time for the first cannulation be decided on a case-
by-case basis.
We recommend that cannulation of the prosthetic AV fis-
tula be initiated 2–4weeks following construction, except in
those of immediate cannulation.
The CSN, KDIGO, NKF-KDOQI, KHA-CARI and NICE pro-
vide no current recommendations on this topic.
Suggestions for future research
Given the lack of high-quality comparative data, randomized
trials comparing decision rules to determine optimal time
points for first cannulation in grafts and fistulas would be infor-
mative. These trials should take care to investigate objective and
reproducible criteria for deciding upon the timing of first can-
nulation of a vascular access. Long-term access outcomes, ad-
verse events and quality of life measures should be reported
transparently.
CHAPTER 7 . VASCULAR ACCESS
SURVEILLANCE
Recommendations
AV fistulas
We suggest the evidence for technical surveillance in
addition to clinical monitoring of a functional arteriove-
nous ﬁstula to detect and pre-emptively correct a hae-
modynamically important arteriovenous access stenosis
in adults is inconclusive and needs more research. (2C)
AV grafts
We suggest against technical surveillance in addition to
clinical monitoring of a functional arteriovenous graft
to detect and pre-emptively correct a haemodynamically
important arteriovenous access stenosis in adults unless
it occurs in the context of a clinical study. (2C)
Advice for clinical practice:
• None.
Rationale
• Background
AV fistulas or grafts can develop stenotic lesions anywhere in
the arteriovenous circuit due to neointimal hyperplasia. This
may lead to dysfunction or thrombosis of the vascular access,
making it unfit for use. It happens quite often and is associated
with an increased risk of irremediable access failure [85].
Clinical monitoring is defined as clinical assessment of an AV
access at regular intervals, including examination of the AV ac-
cess thrill and bruit, haemostasis time after needle removal and
outflow appraisal after arm elevation. Technical surveillance is
defined as the assessment of an AV access at regular intervals
using a specialized apparatus. Both clinical monitoring and
technical surveillance have been advocated under the assump-
tion that detection of a haemodynamically important AV access
stenosis (>50% reduction in luminal diameter) and subsequent
intervention to prevent further vessel narrowing and thrombo-
sis leads to improved longevity of the AV access compared with
salvage interventions deferred to when the access becomes dys-
functional [2, 86]. However, such a practice may inadvertently
lead to more invasive diagnostic and therapeutic interventions
and expose patients to the complications thereof.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 7)
(Supplement 4j Search strategies—Chapter 7)
(Supplement 5j Study selection flow diagrams—Chapter 7)
(Supplement 6j Summary evidence tables—Chapter 7)
A Cochrane systematic review, with content assessed as up
to date through 30 November 2015, included 30 reports of 14
RCTs comprising 1390 participants [87]. Nine studies enrolled
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adults without a documented or suspected access stenosis (pri-
mary prophylaxis) and five enrolled adults with either a docu-
mented or suspected stenosis in a functioning access (secondary
prophylaxis). In primary prophylaxis, pre-emptive correction fol-
lowed the identification of a stenosis using various technical sur-
veillance strategies: Doppler ultrasound, sequential access blood
flow measurements or measurements of dialyser outlet pressure,
often in addition to clinical monitoring. In secondary prophy-
laxis, participants were randomized either before or after angio-
graphic confirmation of a stenosis to pre-emptive correction or
continued monitoring until the access became dysfunctional.
Five studies included only AV fistulas, eight only AV grafts and
one included both. Follow-up ranged from 6 months to 3 years.
Attaining a maximum 11/11 on the AMSTAR checklist, we con-
sidered the review to be of high quality and its results trustwor-
thy. In what follows, we summarize the findings of that review.
A meta-analysis including data from five randomized trials
indicated that pre-emptive correction had uncertain effects on
patient death. The point estimate favoured no intervention, but
the CI spanned a potentially important reduction and increase
in risk, such that the overall level of evidence for the effect was
very low [87].
Pre-emptive correction may have slightly reduced perma-
nent access loss. Both because of the high risk of bias in the in-
cluded studies and the width of the CI, the certainty of the
evidence was low. The authors of the review decided to sub-
group studies according to whether participants had an AV fis-
tula or an AV graft and concluded that pre-emptive correction
may reduce the risk of permanent access failure in AV fistulas
but may make little or no difference in AV grafts. From visual
inspection of the forest plots, we understand the decision to
conduct the subgroup analysis, although there was no statistical
indication of heterogeneity in the primary analysis. Hence the
evidence supporting a claim of differential effect remains low.
Similarly, the effect does not seem to have depended on whether
studies covered primary or secondary prophylaxis, on the type
of surveillance strategy used or on the type of remedial proce-
dure performed.
Twelve RCTs assessed the effect of pre-emptive correction
on access thrombosis (possibly remediable access failure).
Overall, pre-emptive correction slightly reduced the risk of ac-
cess thrombosis, but there was a moderate degree of heteroge-
neity in the analysis that could be explained by the modifying
effect of access type. In the subgroup analysis, there was moder-
ate-certainty evidence for an important reduction in the risk of
possibly remediable failure of an AV fistula. Conversely, there
seemed to be little or no effect on the risk of possibly remediable
failure of an AV graft. Another source of heterogeneity involved
the aim of prevention. In the subgroup analysis, the data indicated
that the effect may be different for people in whom a stenosis was
already suspected or documented (secondary prophylaxis) versus
those in whom that was not the case (primary prophylaxis), but a
lot of heterogeneity remained in the analyses. In primary prophy-
laxis, the type of surveillance strategy had no visual or statistical
influence on the effect of pre-emptive strategies.
For infections, the evidence was very limited. Only three
RCTs included in the review assessed this outcome, but all three
defined the outcome differently: one did not provide a
definition, one included only access infections and one only
catheter-related infection. Given that pre-emptive correction
may decrease catheter use (see below), effects on catheter-
related infection and AV access infection are expected and in-
deed appeared to be in opposite directions, invalidating meta-
analysis of these studies in our view. At this point in time, it
remains unclear how the intervention affects net infection risk,
as no study assessed both outcomes in the same study.
Pre-emptive correction probably increases the number of di-
agnostic angiograms in people that receive primary surveillance of
their AV access, and undoubtedly in those who already have a sus-
pected stenosis based on the clinical monitoring or other technical
surveillance strategies (moderate certainty evidence). It may de-
crease catheter use, and the risk of hospital admission, but the level
of evidence remains low due to the risk of bias in the primary stud-
ies and a large amount of unexplained heterogeneity in the analysis
with point estimates on opposite sides of the line of no effect.
In addition to the Cochrane review, we identified two reports
of another recent randomized trial that had not yet been in-
cluded in the systematic review [88, 89]. The study enrolled 212
adults who had dialysed successfully via an AV fistula for the
past 3 months. Participants were randomized to a ‘classic’ or
‘access blood flow-based’ surveillance programme. The classic
surveillance programme included clinical monitoring, that is,
physical examination of the AV fistula before every dialysis,
and ‘first-generation’ or ‘classic’ technical surveillance through
effective blood flow, dynamic dialyser inlet and outlet pressure
measurement during every dialysis, weekly Kt/V assessment
and recirculation measurement using the urea method every 3
months. The presence of any of the seven alarm criteria would
trigger fistulography and subsequent percutaneous translumi-
nal angioplasty or surgical intervention depending on the find-
ings. The access blood flow-based surveillance programme
included Doppler ultrasound and Doppler dilution methods to
assess blood flow in addition to what was used in the classic sur-
veillance programme on a 3-month basis. Classic criteria would
trigger additional access blood flowmeasurement. A set of three
criteria (blood flow decrease >25%; blood flow <500mL/min,
>50% reduction in vessel diameter plus either peak systolic
blood velocity>400 cm/s or pre-: post-stenosis ratio>3) would
trigger fistulography and subsequent treatment if necessary. At
the end of a 3-year follow-up—with staggered censoring—they
found an important increase in thrombosis-free patency
[Hazard Ratio (HR) 0.38 (95% CI 0.11–0.82)] and access sur-
vival until abandonment [HR 0.49 (95% CI 0.26–0.93)] for
those receiving access blood flow–based surveillance.
Intervention-free access survival was similar [HR 0.98 (95% CI
0.57–1.61)]. Also, the number of interventions during the entire
follow-up was not different (0.14/patient/year in both groups).
• Translation of the evidence into recommendations
For a screening programme to be successful, two important ele-
ments are needed. Not only should the screening test be effec-
tive at detecting the presence of an underlying significant
stenosis, there should also be evidence that subsequent correc-
tion of the stenosis prolongs AV access survival.
In weighing benefits against harms, the GDG assigned the
most value to patient survival and permanent access loss.
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The evidence to date indicates that technical surveillance
and subsequent pre-emptive correction of an AV access steno-
sis may possibly and slightly reduce the risk of permanently los-
ing an AV fistula. It also appears that this effect may be smaller
for AV grafts, if it exists at all. This is regardless of which sur-
veillance technique is used or which intervention is subse-
quently performed. In addition, there is moderate quality
evidence that even possible remediable access failure is probably
not importantly reduced by pre-emptive intervention, whatever
the intervention may be.
For AV fistulas, technical surveillance and pre-emptive
correction seem to have a larger effect than the overall esti-
mate indicated, but caution is required in interpreting both
the relative and absolute effect sizes obtained by the review.
First, although visual inspection of the forest plot indicated ef-
fect modification by access type, there was no statistical indi-
cation that heterogeneity truly exists. Translating the
obtained subgroup effect estimate may thus overestimate the
true effect. A more conservative estimate assumes the overall
relative risk of 0.8 with its CI. The corresponding absolute ef-
fect heavily depends on the baseline risk of access failure in
the control group, which is expected to be (much) larger in
the people already suspected to have an access stenosis than
in those who are not. By estimating the baseline risk from the
studies, the relative effect of 0.8 translates into an estimated
five fewer AV fistulas being lost for every 100 patients
screened and an estimated six fewer for every 100 patients un-
dergoing pre-emptive correction of a documented stenosis af-
ter 1 year. There is better quality evidence for AV fistula
thrombosis. There is moderate quality evidence that surveil-
lance and pre-emptive correction moderately reduce the risk
of fistula thrombosis, the RR of 0.5 translating into an esti-
mated absolute 15 fewer AV fistula thromboses for every 100
patients surveilled for 1 year and an estimated 23 for every
100 patients undergoing pre-emptive correction of a docu-
mented stenosis. This needs to be weighed against the in-
creased number of diagnostic angiograms, which may
ultimately not change the number of invasive procedures a
person needs to undergo. The value patients put on being able
to have these planned—in case of surveillance—rather than
having to undergo them in an emergency setting—in the case
of access thrombosis—may sway the balance of perceived
benefits and harms. Fewer catheters may be required, but the
overall effect on the infection rate remains unclear to date.
Additional demands on individual radiology services may also
limit the feasibility of routine surveillance programmes. Because
of uncertainties around the absolute reduction in risk of AV fis-
tula failure, which needs to be weighed against an increased
number of diagnostic angiograms, the GDG ultimately refrained
from speaking out for or against technical surveillance.
A more recent RCT compared two strategies of surveillance:
‘classic’ or first-generation versus ‘classic plus access blood
flow–based’ or second-generation surveillance [88]. There was
moderate evidence that access blood flow–based surveillance
resulted in reduced access thrombosis and reduced AV fistula
abandonment without increasing the total number of interven-
tions the patients had to undergo. Although this does not di-
rectly answer the question, it seems to indicate the superiority
of access blood flow–based surveillance over classic surveillance
methods. However, the guideline development group felt that at
this stage more research was needed before any specific recom-
mendation could be made.
Other guidelines on this topic
ESVS [34]
Routine physical examination is recommended for vascular
access surveillance and maintenance. (I-B)
It is recommended that vascular access monitoring be per-
formed by flow measurement of AV grafts monthly and AV fis-
tulas every 3months. (I-B)
When AV fistula blood flow measurement during dialysis
indicates the presence of a vascular access stenosis, that is, Qa is
<500mL/min, angiographic assessment of stenosis should be
considered. (IIa-B)
Venous pressure adjusted for a mean arterial pressure>0.50
(or derived static venous pressure >0.55) is not a reliable indi-
cator of stenosis and intervention based on this finding is not
recommended. (III-C)
When haemodialysis efficiency is impaired, investigation
and correction of an underlying vascular access stenosis should
be considered. (IIa-B)
Surveillance of AV fistulas with duplex ultrasound at regular
intervals and pre-emptive balloon angioplasty should be consid-
ered to reduce the risk of AV fistula thrombosis. (IIa-A)
Surveillance of AV grafts with duplex ultrasound at regular
intervals and pre-emptive balloon angioplasty is not recommended
to prevent thrombosis or improve AV graft functionality. (III-A)
CSN [90]
Measure access flow bimonthly in AV fistulas and venous
pressure or access flowmonthly in AV grafts. (Grade D)
Perform angiography if fistula flow decreases to <500mL/
min or drops to >20% from baseline (Grade D) or if AV graft
flow decreases to <650mL/min or drops >20% from baseline.
(Grade D)
NKF-KDOQI [86]
Prospective surveillance of fistulas and grafts for haemody-
namically significant stenosis, when combined with correction
of the anatomic stenosis, may improve patency rates and may
decrease the incidence of thrombosis.
The work group recommends an organized monitoring/sur-
veillance approach with regular assessment of clinical parame-
ters of the AV access and HD adequacy. Data from the clinical
assessment and HD adequacy measurements should be col-
lected and maintained for each patient’s access and made avail-
able to all staff. The data should be tabulated and tracked within
each HD centre as part of a quality assurance programme.
Physical examination should be used to detect dysfunction in
fistulas and grafts at least monthly by a qualified individual. (B)
Techniques, not mutually exclusive, that may be used in sur-
veillance for stenosis in grafts include:
• Preferred:
 intra-access ﬂow by using one of the several methods
that are outlined in Table 7 using sequential measure-
ments with trend analysis (A)
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 directly measured or derived static venous dialysis pres-
sure by one of the several methods (A) (Protocol pro-
vided in Table 8 for using transducers on haemodialysis
machines to measure directly; criteria in Table 9 for de-
rived methods.)
 duplex ultrasound (A).
• Acceptable:
 physical ﬁndings of persistent swelling of the arm, presence
of collateral veins, prolonged bleeding after needle withdrawal
or altered characteristics of pulse or thrill in a graft (B).
• Unacceptable:
 unstandardized dynamic venous pressures should not be
used.
Techniques, not mutually exclusive, that may be used in
surveillance for stenosis in AV fistulas include:
• Preferred:
 direct ﬂow measurements (A)
 physical ﬁndings of persistent swelling of the arm, pres-
ence of collateral veins, prolonged bleeding after needle
withdrawal or altered characteristics of pulse or thrill in
the outﬂow vein (B)
 duplex ultrasound (A).
• Acceptable:
 recirculation using a non-urea-based dilutional method
(B)
 static pressures (B) direct or derived (B).
One should not respond to a single isolated abnormal value.
With all techniques, prospective trend analysis of the test pa-
rameter has greater power to detect dysfunction than isolated
values alone (A).
Persistent abnormalities in any of the monitoring or surveil-
lance parameters should prompt referral for access imaging (A).
There should be an access flow rate <600mL/min in grafts
and<400–500mL/min in fistulas (A).
There should be a venous segment static pressure (mean
pressures) ratio>0.5 in grafts or fistulas (A).
There should be an arterial segment static pressure ratio
>0.75 in grafts (A).
NICE [91]
Quality standard: Adults receiving haemodialysis have their
vascular access monitored and maintained using systematic
assessment.
GEMAV [35]
We recommend performing a complete physical examina-
tion of the AV access in every advanced CKD clinic visit to as-
sess maturation and to detect early on any complication before
the first cannulation.
We recommend that Doppler ultrasound be performed if in-
sufficient development of a native AV fistula is observed during
physical examination in regular advanced CKD outpatient
check-ups.
We recommend that haemodialysis units have protocolized
programmes for AV fistula follow-up, involvingmultidisciplinary
participation. These programmes should include methods for
early diagnosis of AV fistula dysfunction and locate its origin, as
well as performing the elective treatment.
We recommend that the application of programmes for AV
fistula follow-up must involve periodic assessment of the
parameters obtained by each monitoring and/or surveillance
method applied.
We recommend that repeated alteration of any monitoring
and/or surveillance parameter be used as a criterion to perform
an imaging examination of the AV fistula in front of suspected
pathology.
We recommend that both Doppler ultrasound and dilution
screening methods be used interchangeably to assess AV fistula
function, as they have an equivalent performance for blood
flow determination.
We recommend that Doppler ultrasound be used as the
first-choice imaging test in the hands of an experienced exam-
iner, without the need for confirmatory fistulography, to indi-
cate elective treatment in the event of suspected significant
stenosis.
We recommend that fistulography be reserved as a diagnos-
tic imaging exploration only for cases with inconclusive
Doppler ultrasound findings and persistent suspicion of signifi-
cant stenosis.
According to the current concept of significant stenosis, we
do not recommend that surveillance of the prosthetic AV fistula
be performed using second-generation screening methods,
whether there are dilution methods to estimate the blood flow
or Doppler ultrasound.
According to the current concept of significant stenosis, we
recommend that first-generation screening methods be used for
monitoring the prosthetic AV fistula.
According to the current concept of significant stenosis, we
recommend that both first- and second-generation methods be
used for monitoring and surveillance of the native AV fistula.
We recommend that a stenosis be considered significant
when there is any reduction in the vascular lumen in native or
prosthetic AV fistulas, shown by Doppler ultrasound, that
meets all the criteria for high risk of thrombosis (the two main
criteria and at least one additional criterion).
We recommend that an elective intervention be performed
without delay by percutaneous transluminal angioplasty and/or
surgery when the diagnosis of significant AV fistula stenosis is
established because of the high risk of thrombosis.
We recommend that a stenosis be considered non-
significant when there is any reduction in the vascular lumen in
native and prosthetic AV fistulas, shown by Doppler ultra-
sound, that does not meet all the criteria for high risk of
thrombosis.
We recommend that an elective intervention not be per-
formed when a diagnosis of non-significant stenosis is estab-
lished in an AV access because of the low risk of thrombosis.
We recommend that all non-significant AV fistula stenosis
be strictly controlled using second-generation screening meth-
ods, because the risk of progression is significant.
We recommend that an elective intervention be performed
on the dysfunctional AV fistula with significant stenosis instead
of restoring after thrombosis.
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We suggest surgical treatment of juxta-anastomotic stenosis
of the native AV fistula be performed provided a central venous
catheter does not need to be placed.
We suggest venous juxta-anastomotic stenosis of the pros-
thetic AV fistula be treated indistinctly by angioplasty or surgi-
cal intervention.
We suggest non-juxta-anastomotic stenosis of the native AV
fistula initially be treated using angioplasty, because it is less in-
vasive than surgery.
We recommend fistulography be performed if central ve-
nous stenosis is clinically suspected.
We recommend only central vein stenoses that are symp-
tomatic be treated.
We recommend endovascular therapy be performed using
percutaneous transluminal angiography with balloon as the first
treatment option for central stenosis.
We suggest the use of stents be limited to selected cases where
there is technical failure of angioplasty and frequent relapse of ste-
nosis, and we recommend they be not used in venous confluents.
We suggest that angioplasty be used as the initial treatment in
stenosis in the cephalic vein arch. Treatment by stent placement or
by surgical transposition of the cephalic veinmay also be considered.
UK Renal Association [92]
We recommend that all patients on long-term haemodialysis
should have their vascular access monitored and maintained to
minimize failure, to allow timely planning for subsequent re-
placement with definitive vascular (or peritoneal) access and to
avoid the need for emergency access. (1B)
We suggest that systematic observation and advanced sur-
veillance should be employed to predict and prevent access fail-
ure. (1C)
The KDIGO and KHA-CARI provide no current recommenda-
tions on this topic.
Suggestions for future research
Given the possible, but insufficiently clear, benefits of
screening and subsequent pre-emptive correction of an estab-
lished stenosis in functioning AV fistulas, an adequately pow-
ered RCT assessing the right outcomes (AV fistula loss, death,
quality of life, infections) would be informative. As screening
can only be useful if interventions for correcting established AV
fistula stenosis are effective, it would be pragmatic to enrol only
participants with a suspected or documented access stenosis.
An informative RCT would include meticulous records of how
many patients were screened, how often, what monitoring and
surveillance methods were used and how much staff time was
spent on access screening, data collection and interpretation.
Ravani et al. [87] estimated that based on the findings of their
review, an RCT of 1020 participants per arm recruited over 1
year and followed for 3 years would have a power of 90% to de-
tect a 30% reduction in the HR for access loss as significant at a
two-sided P-value of 0.01, assuming a baseline risk of 10% and
a withdrawal rate of 10%. To better inform the best practice rec-
ommendations in this field, patient preferences concerning the
various outcomes and their views on elective versus urgent in-
tervention should be included in future research.
CHAPTER 8 . MEDICAL TREATMENTS FOR
MAINTAINING LONG-TERM AV ACCESS
PATENCY
Recommendations
AV fistulas
We suggest any decision to give ﬁsh oil to adults with end-
stage kidney disease in the year after arteriovenous ﬁstula
creation must balance improved patency at 1 year against
an unknown risk of bleeding and other side effects. (2C)
We suggest that far infrared therapy may be considered
for improving long-term arteriovenous ﬁstula patency in
adults with end-stage kidney disease (2C)
There are insufﬁcient RCT data to make a recommenda-
tion for aspirin, clopidogrel, ticlopidine, warfarin, sulphin-
pyrazone, vonapanitase, beraprost sodium, cholecalciferol,
statins, dipyridamole or dipyridamole combined with aspi-
rin to be given for maintaining long-term arteriovenous
ﬁstula patency in adults with end-stage kidney disease (-D)
AV grafts
We recommend against warfarin in combination with
antiplatelet agents and against clopidogrel in combination
with high-dose aspirin for reducing arteriovenous graft
thrombosis in adults with end-stage kidney disease (1C)
We suggest that any decision to give ﬁsh oil in the year fol-
lowing arteriovenous graft creation in adults with end-stage
kidney disease must balance any improvement in graft pa-
tency at 1 year against an unknown risk of bleeding. (2C)
There are insufﬁcient RCT data to make a recommendation
for aspirin, clopidogrel, ticlopidine, warfarin, beraprost so-
dium, statins, dipyridamole or dipyridamole combined with
aspirin to be given for maintaining long-term arteriovenous
graft patency in adults with end-stage kidney disease (-D)
Advice for clinical practice:
• None.
Rationale
• Background
AV fistulas or grafts can develop stenotic lesions anywhere in the
AV circuit, mostly due to neointimal hyperplasia. This may lead to
dysfunction or thrombosis of the vascular access, making it unfit
for use. AV access thrombosis happens quite often and is associ-
ated with an increased risk of irremediable access failure [85].
Several medications, including antiplatelet agents and vitamin K
antagonists, are thought to prevent AV access thrombosis and in-
crease AV access patency and longevity but may also cause bleed-
ing [93]. As immediate maturation problems in the first weeks and
months after access creation may result from different pathophysi-
ological factors than patency problems in the long run, the two
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issues are discussed in two different sections. In this chapter we as-
sess long-term patency; maturation is discussed in Chapter 1.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 8)
(Supplement 4j Search strategies—Chapter 8)
(Supplement 5j Study selection flow diagrams—Chapter 8)
(Supplement 6j Summary evidence tables—Chapter 8)
Five systematic reviews of RCTs assessing benefits and
harms of various medical adjuvant treatments to increase pa-
tency of AV fistulas and AV grafts were identified. We judged
all these reviews to be of moderate to high quality, with
AMSTAR scores of 8–10/11 [14–18]. All the reviews included
both studies measuring patency outcomes after 6–12weeks as
well as patency outcomes measured several months later. Based
on group consensus, for this section we chose to only consider
studies measuring patency outcomes after 12weeks, as an arbi-
trary cut-off to distinguish maturation from long-term patency.
The first was a Cochrane systematic review with content
assessed as up to date through 23 March 2015 [14]. It included
15 RCTs comprising 2230 participants. Seven trials included
people with an AV fistula, six with an AV graft and two with ei-
ther an AV fistula or AV graft. After exclusion of the studies on
maturation (outcomes registered within 12weeks of creation),
nine studies remained for consideration in the present section.
Three of these included AV fistulas and the remaining six in-
cluded AV grafts. All but one enrolled participants at the time
of AV access insertion [20]. Tested medical interventions in-
cluded aspirin, dipyridamole, dipyridamole plus aspirin, warfa-
rin, fish oil, clopidogrel and human type I pancreatic elastase.
Studies mostly included participants of all ages, follow-up
ranged from 5 to 18months after AV access insertion. Most
studies only assessed AV access thrombosis as the primary out-
come of interest.
The second was also a Cochrane systematic review that cov-
ered specifically anti-platelet agents to prevent vascular access fail-
ure and other outcomes in people with CKD, with content
assessed as up to date through 24 January 2011 [15]. Most of the
data contained in that review were not included in this section, as
outcomes were mostly registered within 3 months of AV access
creation. This systematic review focused only on the effect of anti-
platelet agents, and the included studies largely overlapped with
the ones that Tanner et al. [14] later included in their review. In
contrast to that review, the second review also included existing
access systems [15], which resulted in the identification of two ad-
ditional RCTs for this guideline section [94, 95].
Three other systematic reviews each assessed a specific treat-
ment: fish oil [16] and far infrared therapy [17, 18].
In addition to these reviews, a further three RCTs, published
after 2013 and not included in any of the included systematic
reviews, assessing various adjuvant medical treatments for im-
proving patency were identified [24, 25, 96].
Aspirin
Two RCTs compared different doses of aspirin versus pla-
cebo in AV grafts with overall very uncertain effect on AV ac-
cess thrombosis [20, 97]. The two included studies were small
and at unclear risk of bias, results were very inconsistent and
the CI was very wide, spanning the line of no effect.
A third RCT compared 30mg of aspirin daily versus placebo
in a random crossover design in 137 patients who had been on
haemodialysis for >6 weeks while treated with erythropoietin
[95]. The investigators found no appreciable difference in
thrombosis or loss of patency. They reported no data on adverse
outcomes.
Clopidogrel
A first RCT assessed the combination of clopidogrel and aspi-
rin versus placebo for AV graft outcomes in newly inserted AV
grafts [94]. The study was terminated early after 12months be-
cause of excessive bleeding risk in the active treatment arm.
Antiplatelet treatment did not alter thrombosis or loss of patency.
A second study randomized 96 participants to receive either
clopidogrel plus a prostacyclin analogue or placebo for 7 days
before until 1 year after AV fistula creation [24]. The investiga-
tors described an important reduction in primary fistula failure
at 1 year. They reported no bleeding, but the external validity of
the results was considered low because of stringent exclusion
criteria. Only 25% of all the people set to undergo AV fistula
creation had been enrolled.
Dipyridamole
One RCT tested the effect of dipyridamole or dipyridamole
plus aspirin versus placebo on thrombosis within 18months in
people with newly inserted AV grafts [97]. The point estimate
favoured dipyridamole in both cases, but the certainty of the ev-
idence was low due to an unclear risk of selection and selective
reporting bias, as well as a very wide CI spanning both an im-
portant reduction and increase in graft thrombosis. Again, the
publication contained no clear data on adverse events.
Anticoagulants
One RCT assessed low-dose warfarin in newly inserted AV
grafts, targeted to an international normalized ratio of 1.4:1.9
[98]. Warfarin did not decrease graft thrombosis, and the study
was terminated early for major bleeding complications in the
treatment group. Five patients (11% of participants) on warfa-
rin developed severe bleeding (including upper gastrointestinal
bleeding and cerebral haematoma). All five patients were con-
currently treated with antiplatelet agents. Those in the placebo
arm had no severe bleeding.
Fish oil, omega 3 polyunsaturated fatty acids
One systematic review compared fish oil versus placebo or
no treatment, with the content assessed as up to date through
January 2017 [16]. In addition to two RCTs identified by
Tanner et al. [14], this review included four additional RCTs
assessing dosages ranging from 3 g three times weekly to 6 g
daily. Only one study assessed the effect in AV fistulas, the
others were in AV grafts. In the meta-analysis, the authors
found moderate-certainty evidence suggesting that fish oil
treatment using 1.6–3.4 g of polyunsaturated fatty acids for 12–
52weeks prevented primary patency loss. There was no evi-
dence for a differential effect between AV fistulas and grafts. It
was very uncertain whether fish oil increased the risk of
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bleeding. No data were provided for the severity or nature of
bleeding for most studies.
Statins
There were no RCTs for long-term outcomes of statins.
Vonapanitase, recombinant type I pancreatic elastase
Three RCTs assessed the effect of recombinant type I pan-
creatic elastase applied directly to the adventitia of the AV ves-
sels at the time of access creation [14]. At 12months, the agent
seemed to reduce the odds for AV access thrombosis, although
the certainty of the evidence was low due to a risk of bias in the
included studies and important imprecision with a CI spanning
the line of no effect.
All three studies listed several adverse events including local
symptoms secondary to the creation of a new AV access, but
according to the study authors, there were no significant differ-
ences between placebo and recombinant type I pancreatic
elastase–treated participants.
We found an additional trial that randomized 313 people to
locally dripped vonapanitase or placebo [25]. At 1 year, the
authors found very little evidence for a difference in their pri-
mary outcome of unassisted patency. Secondary patency was
13% higher in the group treated with vonapanitase, but no ab-
solute numbers were given and the risk of bias assessment was
hampered by the study being published as an abstract only.
Beraprost sodium
One RCT assessed the effect of beraprost sodium, an oral
synthetic analogue of prostaglandin I2, on 2-and 1-year primary
unassisted patency in 55 patients with a previously failed AV
access. In 75% the new access was an AV fistula and in the
remaining quarter an AV graft. After 2 years, those who had re-
ceived beraprost were about three times as likely to have a pat-
ent AV access than those who had not. However, the study was
considered at high risk of bias due to unclear randomizing, lack
of blinding and insufficiently detailed numeric outcome report-
ing. The authors reported no important bleeding events in ei-
ther group, but external validity may be questioned since people
considered at increased risk of bleeding had been excluded
from the study.
Far infrared therapy
There was one systematic review on far infrared treatment to
increase the patency of AV fistulas, with content assessed as up
to date through January 2017 [18]. The review included 21
RCTs comprising 1899 participants at the time of access crea-
tion. Although not clearly reported, it appears all studies in-
cluded people with an AV fistula. Investigators used different
strategies for delivering far infrared rays; most commonly, a de-
vice generating wavelengths between 5 and 25mm, set at a
height of 20 cm above the AV fistula, with a treatment time of
40min during each haemodialysis session. Most studies
assessed blood volume, vessel diameter or primary patency at
various time points up to 1 year after fistula creation. Although
the reliability of the evidence was compromised by the small
number of studies and research groups these data were derived
from and the risk of bias in the underlying studies, overall far
infrared therapy seemed to increase primary unassisted patency
at 12months. In addition, five trials comprising 510 participants
showed results for AV fistula occlusion rates. Overall, therapy
with far infrared radiation decreased AV fistula occlusion rates.
There was no evidence of heterogeneity in these trials.
An older review included only four RCTs, comprising
666 patients [17]. Primary unassisted patency was assessed in
610 patients and far infrared therapy for 40min three times
weekly seemed to improve primary unassisted patency com-
pared with controls. In addition, the two studies that reported
secondary patency rates indicated a small difference in favour
of far infrared therapy. The reliability of the results was mainly
limited due to the high risk of bias by being open-label, being
conducted by the same research group and being industry
sponsored.
• Translation of the evidence into recommendations
The GDG felt that for a positive recommendation, interventions
had to improve successful use of the AV access. It was judged
that in the absence of evidence for a positive effect of successful
cannulation, evidence for an effect on access thrombosis would
not be enough to advocate treatment. Although it is true that
access thrombosis precludes successful use of the fistula for dial-
ysis, a reduction in access thrombosis does not necessarily
translate into improved patency. If these interventions, pre-
dominantly aimed at reducing platelet aggregation and coagula-
tion, increase the risk of bleeding, then a local haematoma may
cause irremediable access loss. In contrast, access thrombosis
may be treated with endovascular or surgical procedures,
whereby patency is maintained or restored. In general, there
were very few studies suggesting a positive effect of a given in-
tervention and positive outcomes were rarely confirmed by in-
dependent sources. Often though, rather than formulating a
neutral statement, the group also wanted to highlight existing
ambiguity by communicating the items to be weighed in deci-
sion making.
Other guidelines on this topic
ESVS [34]
Long-term antithrombotic therapy should not be used to pro-
long vascular access patency in haemodialysis patients. (III-C)
GEMAV [35]
We suggest that antiplatelet therapy for thrombosis prophy-
laxis of native AV fistula be indicated on a case-by-case basis,
because although it shows a decrease in the risk of thrombosis,
we consider that adverse effects have not been studied with suf-
ficient accuracy.
We suggest that antithrombotic prophylaxis not be used in
patients with prosthetic AV fistulas because there is no benefit
in preventing thrombosis and the adverse effects have not been
studied with sufficient accuracy.
UK Renal Association [92]
We recommend that pharmacological and mechanical
strategies are in place to maintain or restore access patency. (1C)
The CSN, KDIGO, KHA-CARI, NKF-KDOQI and NICE pro-
vide no current recommendations on this topic.
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Suggestions for future research
The small number of studies with their short follow-up, few
participants and mostly single-centre approach precluded the
formulation of any definitive recommendation. Many studies
did not assess bleeding, infection or obstruction of the in- or
outflow. Adverse events were often not considered or inade-
quately reported (e.g. systemic bleeding). Any future controlled
study should try and close this gap.
Assessment of the evidence highlights the ambiguity of ‘mat-
uration’ as an outcome. Some studies assess outcomes up to 1 year
after the creation of an AV access and still refer to the study as
evaluating maturation. Given that principles governing matura-
tion may be different from those maintaining long-term
patency, a decision was made to assess the two outcomes sepa-
rately. To allow the distinction, we required>3 months of follow-
up for including studies in the current chapter. To facilitate inter-
pretation, future work should focus on establishing clear defini-
tions for concepts that are frequently used but currently ill-
defined. Determining core outcomes and harmonizing
their measurement would facilitate comparison and interpretation
of study results. Perhaps the SONG initiative, which aims to estab-
lish core outcomes in CKD, will bring more consistency in the ter-
minology of outcome reporting in dialysis access studies [4].
CHAPTER 9. CANNULATION TECHNIQUES
FOR AV FISTULAS
Recommendations
We suggest against using the area technique for cannu-
lating arteriovenous ﬁstulas in adults treated with hae-
modialysis. (2D)
We suggest using either a rope-ladder or buttonhole tech-
nique for cannulating arteriovenous ﬁstulas in adults treated
with haemodialysis and letting the choice be dependent on
local expertise and arteriovenous ﬁstula characteristics. (2D)
Advice for clinical practice:
• Antiseptic measures and practical aspects of the cannula-
tion procedure are important in reducing the infection
risk associated with buttonhole cannulation.
• AV grafts are usually only cannulated using a rope-ladder
technique.
Rationale
• Background
Proper cannulation of the AV access is the key to its preserva-
tion and prevents vascular access–related morbidity. While
AV grafts are only cannulated using a rope-ladder technique,
three different methods for puncture site selection exist for
AV fistulas: the area, rope-ladder and buttonhole techniques
(Figure 1). The area technique refers to cannulating the same
general area, but not necessarily the same point, session after
session. In the rope-ladder technique, the cannulator rotates
needle placement sites for each dialysis along the entire length of
the cannulation segment. Both these techniques require the use
of sharp—cutting—needles and allow skin healing after each
haemodialysis session. In the buttonhole method, haemodialysis
needles are inserted at the same site, angle and depth for consec-
utive dialysis sessions, using blunt—non-cutting—needles in a
fibrotic track previously created by sharp needles.
The buttonhole technique has been advocated to facilitate
cannulation, decrease needling pain, reduce bleeding at the
end of the haemodialysis session and prevent aneurysm de-
velopment. However, it is unclear whether these benefits re-
ally exist, how they balance with infection risk and whether
technique choice influences long-term AV fistula patency.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 9)
(Supplement 4j Search strategies—Chapter 9)
(Supplement 5j Study selection flow diagrams—Chapter 9)
(Supplement 6j Summary evidence tables—Chapter 9)
Three systematic reviews were identified [99–101], including
six reports of five RCTs comparing buttonhole with ‘control’
cannulation in AV fistulas [102–107]. The included RCTs
reported on patient survival, access survival, quality of life, nee-
dling pain, infection, bleeding during or after dialysis and aneu-
rysm development. Outcome definitions and measures varied,
hampering formal meta-analysis. All studies included both inci-
dent and prevalent dialysis patients dialysed through an AV fis-
tula. Buttonhole cannulation was compared with other—often
ill-defined—cannulation techniques. One RCT defined the
comparator as ‘different-site technique’, a mix of rope-ladder
and area cannulation not further specified [102]. Another com-
pared buttonhole with standard or control cannulation not fur-
ther specified [103]. Three RCTs compared buttonhole versus
rope-ladder cannulation [104–106]. In all these studies, by defi-
nition, buttonhole cannulation was performed with blunt nee-
dles and the comparator cannulation technique with sharp
needles. Four of five RCTs included only in-centre haemodialy-
sis patients [102–104, 106]. Only one included both home and
in-centre patients [105]. Sample sizes were generally small, in-
cluding between 56 and 140 participants.
Patient survival
One RCT reported eight and five deaths, respectively, in the
groups using buttonhole and other cannulation techniques after
1 year (MD 7%, no statistical testing) [102]. The second RCT
assessed 140 in-centre haemodialysis patients over an 8-week
period, which reported one death in each group [106]. Its 12-
month follow-up study equally reported similar number of
deaths in both groups [107]. Finally, two RCTs also had similar
event numbers in both groups at 6 months [104, 105].
Access survival
After 1 year of follow-up, one RCT had no AV fistula failures
in the buttonhole group. In the group using other cannulation
techniques, the median Interquartile range (IQR) time to fistula
failure was 268 days (IQR 143–292) [102]. In another RCT,
the median access survival was similar for both groups
(17months) [107].
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Primary unassisted patency and secondary patency
In one RCT, both primary unassisted and secondary patency
were substantially better in the buttonhole group than in the
usual practice group (73% versus 48%, no statistical testing;
100% versus 86%; P¼ 0.005) [102]. However, a second RCT
reported no difference in unassisted primary and secondary pa-
tency for buttonhole versus another technique [107].
Thrombosis
One RCT found no difference in thrombosis and the event
rate was generally low [107]. A second RCT observed six cases
of thrombosis with usual practice versus none with buttonhole
[102]. A third RCT found one fistula thrombosis in both
groups [104].
Quality of life
Only one RCT measured quality of life. They randomized 70
adults frommultiple in-centre and home training units to either
buttonhole or rope-ladder cannulation. After 6 months, they
found no difference in any of the measures between the
groups [105].
Cannulation pain
In a systematic review that also included non-randomized
studies, buttonhole was associated with reduced needling pain
in observational studies [standardized mean difference (SMD)
0.76 (95% CI1.38 to20.15 Standard Deviation (SD))] but
not among RCTs [three RCTs; SMD 0.34 (95% CI 0.76–
1.43)] [100].
All five included RCTs assessed patient-reported pain. None
of these were blinded, due to the nature of the intervention, and
all studies were at high risk of detection bias.
One RCT found similar pain scores for buttonhole and
rope-ladder cannulation over an 8-week period (median score
1.5 versus 1.2; P¼ 0.57), but there was some evidence suggest-
ing more people in the buttonhole group who experienced se-
vere pain (pain score>3) (28.6% versus 15.7%; P¼ 0.07) [106].
Of note, the investigators only specified rope-ladder being the
control group cannulation technique in the title of the paper;
detailed information was missing from the methods. All partici-
pants in this study used a topical 5% lidocaine gel. It can be ar-
gued that the standard use of lidocaine decreased the pain
scores, possibly explaining why a difference between cannula-
tion techniques was not seen.
In the second RCT, 8 of 10 patients reported buttonhole to
be less painful than their previous cannulation technique [103].
The remainder reported similar pain levels. Although random-
ized, the trial did not compare pain levels directly and did not
provide the pain scores measured in the control group. One
may also question whether the assessment time frame should
be longer than 1 week.
The third RCT reported a median pain score of 3/10 before
and 2.5/10 after 6 months for patients cannulated using the but-
tonhole technique. The rope-ladder group reported pain scores
of 1/10 at both time points [104]. No statistical analysis was
provided. The use of local anaesthetics was allowed and could
have influenced the pain scores. Patients randomized to the
buttonhole technique used local anaesthetics less frequently.
FIGURE 1: Cannulation techniques: (A) rope-ladder technique, (B)
area technique and (C) buttonhole technique. Reprinted from
Schmidli et al. [33], with permission from Elsevier.
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The fourth RCT found people using the buttonhole tech-
nique reported similar pain scores compared with controls
after 1 year [102]. The use of local anaesthetics was similar in
both groups. And finally, a fifth RCT also found no meaning-
ful difference in pain scores between the buttonhole and
rope-ladder techniques at baseline or at the final follow-up
[105]. Fewer people in the buttonhole group used xylocaine
(44% versus 76.7%; P¼ 0.01). However, five patients using
the buttonhole technique reported site pain during dialysis
(P¼ 0.01).
Infections
A meta-analysis that included data from four RCTs indi-
cated buttonhole cannulation to be associated with a 3-fold
increase in infectious risk with other cannulation techniques
[four RCTs; RR 3.34 (95% CI 0.91–12.20)] [101]. Event
rates varied substantially and CIs crossed the line of no effect
[101].
The first RCT reported one infection—defined as erythema,
redness, swelling, tenderness, exudates or pus—in 37 patients in
the buttonhole group versus none in the control group during 3
months of follow-up [103]. The investigators did not define the
cannulation technique used in the control group. A second
RCT reported one infection in 28 patients in the buttonhole
group during a 6-month follow-up period [104]. There were no
infections in the rope-ladder group. In contrast, a third RCT
reported two cases of bacteraemia in the control group versus
none in the buttonhole group during 1 year of follow-up. There
were, however, two cases of local infection in the buttonhole
group and none in the control group [102]. A fourth study
documented localized infection twice as often in those using
buttonhole versus other techniques during an 8-week observa-
tion period (P< 0.01) [106]. Staphylococcus aureus bacteraemia
was noted once in the buttonhole group and not in the control
group. An 18-month follow-up report described 12 patients us-
ing buttonhole experiencing an infection versus none with stan-
dard care (P< 0.001) [107]. Three of these infections were local
infections and nine were S. aureus bacteraemia. The median
time to first infection was 11months. A fifth RCT reported
four infections in 34 patients in the buttonhole group and one
infection in 35 patients in the rope-ladder group during a 6-
month observation period (P¼ 0.11) [105]. However, the pa-
tient with the infection in the rope-ladder group had been can-
nulated using a buttonhole technique at the time of infection.
Bleeding from cannulation sites during dialysis
One RCT reported severe bleeding (needing an astringent)
at the puncture site during the haemodialysis session in 2.7% of
people using buttonhole versus 4.6% using another cannulation
technique. An additional 11% of people using buttonhole expe-
rienced mild bleeding, versus none in the control group [103].
The authors reported that no statistical analysis and the cannu-
lation technique in the control group were not defined. The sec-
ond RCT reported 11 episodes of bleeding in two patients
during dialysis in the buttonhole group compared with 17 epi-
sodes in the control group. The number of patients affected in
the control group was not reported [104].
Haemostasis after needle removal
Time until haemostasis was<5 min in 54% of patients using
buttonhole compared with 28% for those using the undefined
control technique [103]. The four other RCTs included in the
systematic review by Wong et al. [100] found no appreciable
differences in post-dialysis bleeding times [102, 104–106].
Haematomas
One RCT reported 19 haematomas in the buttonhole group
(8 of which occurred before creation of the buttonhole tract, 7
while creating the buttonhole tract and 4 in established tracks)
compared with 27 hematomas in the rope-ladder group [104].
The second RCT found fewer haematomas with buttonhole
cannulation (295/1000 dialysis sessions with buttonhole versus
436/1000 dialysis sessions with standard cannulation)
(P¼ 0.03) [106]. Also, a greater proportion of patients in the
standard group had at least one haematoma (36% versus 17%;
P¼ 0.01). In contrast, the third RCT reported four haematomas
in 34 patients in the buttonhole group and none in the usual
care group (P¼ 0.03) [105].
Aneurysm development
One RCT assessed the average increase in maximum trans-
verse fistula diameter based on measurements from photo-
graphs taken at baseline and after 6months [104]. Overall, in
the buttonhole group, AV fistulas did not increase in size. In the
rope-ladder group, AV fistulas widened by 30% on average, cor-
responding to an absolute increase of 5mm. The second RCT
found new aneurysms in 4% of patients using a buttonhole can-
nulation technique and in 17% of people using the control tech-
nique [102]. Enlargements of pre-existing aneurysms were
found in 23% of patients in the buttonhole group and in 67% in
the control group. An aneurysm was defined as a swelling of
0.5 cm or an increase in size0.5 cm. Aneurysms were assessed
based on photographs on a 3-month basis. No studies used ul-
trasound to assess aneurysm formation.
• Translation of the evidence into recommendations
The technique used for cannulation of an AV fistula has uncer-
tain effects on patient and access survival. RCT data are scant
and contradictory, making any inference for critical outcomes
quite problematic. Similarly, high-certainty data for quality of
life that could steer judgement in decision making are currently
not available. The supposition that the buttonhole technique
causes less cannulation pain is not supported by current RCTs.
However, the use of local analgesic treatment possibly influ-
enced the extent to which pain could be objectively measured.
In addition, the cannulation technique used in control groups
was ill-defined for most studies.
There is evidence suggesting that the buttonhole technique
leads to an increased risk of local and systemic infections as
compared with rope-ladder cannulation. However, the GDG
felt that risk may be somewhat modified through appropriate
antiseptic measures. There is also low-certainty evidence from
two studies suggesting that buttonhole cannulation causes less
extensive aneurysm formation, although patency rates appear
to be similar.
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The GDG felt the RCT evidence base did not allow a clear
recommendation in favour of a specific cannulation technique.
In the absence of such evidence, they felt their advice should in-
corporate a large observational study including>7000 patients,
indicating the area technique to be associated with poorer AV
fistula survival than the other two techniques [108].
The group felt it reasonable to support both rope-ladder and
buttonhole cannulation techniques according to centre expertise,
AV fistula characteristics and patient preference. Often the length
of the fistula cannulation segment will dictate whether to opt for
buttonhole or rope-ladder. The GDG also agreed that all centres
would benefit from maintaining a minimal level of experience
with the different techniques within the vascular access team.
From the observational data, it becomes apparent that
there is large variability in how different techniques are
applied in clinical practice. A single label (buttonhole, rope-lad-
der, area cannulation) often covers different practices, which
complicates interpretation of the evidence that is available. In
that perspective, the GDG advised to have a quality improve-
ment programme in place where outcomes of cannulation are
registered and analysed at regular intervals.
Other guidelines on this topic
CSN [109]
For adult end-stage renal disease patients receiving intensive
home haemodialysis with an AV fistula, we suggest the use of
rope-ladder cannulation over buttonhole cannulation unless
topical antimicrobial prophylaxis is used. (2D)
For adult end-stage renal disease patients using buttonhole
cannulation for intensive home haemodialysis, we suggest the use of
mupirocin antibacterial cream to reduce the risk of infection. (2D)
ESVS [34]
In patients with a short cannulation segment, the use of the
buttonhole technique should be considered over other techni-
ques. (IIIa-C)
KHA-CARI [110]
Comparedwith the rope-ladder technique, the buttonhole tech-
nique is associated with an increased risk of local and systemic in-
fection and should not be routinely performed. (Level II evidence)
NKF-KDOQI [86]
Patients with fistula access should be considered for button-
hole cannulation and for self-cannulation, the buttonhole is the
preferred technique.
GEMAV [35]
We recommend that the rope-ladder technique be used as
the method for cannulating a prosthetic AV fistula.
We recommend that the rope-ladder technique be used as
the preferred method for cannulating native AV fistulas.
We recommend that the buttonhole technique be reserved
for cannulating tortuous or deep native AV fistulas and/or
those with an extremely short venous length.
UK Renal Association [92]
We recommend that the rope-ladder and buttonhole techni-
ques should be used for cannulation of AV fistulas and rope-
ladder for AV grafts. (2B)
KDIGO and NICE provide no current recommendations on
this topic.
Suggestions for future research
Long-term RCTs are needed for comparing buttonhole with
other cannulation techniques in incident haemodialysis patients.
Such studies should measure pain using validated methods
[111]; be adequately powered for infection, patency and quality
of life and include detailed reporting of complications.
CHAPTER 10 . NEEDLE TYPES FOR AV
FISTULAS
Recommendations
We suggest using either sharp needles or plastic cannu-
las for cannulating arteriovenous ﬁstulas in adults
treated with haemodialysis. (2C)
We recommend using blunt needles only for buttonhole
cannulation of arteriovenous ﬁstulas in adults treated
with haemodialysis. (1D)
Advice for clinical practice:
• A quality improvement programme including recording
and monitoring of the needle types and cannulation tech-
niques alongside with AV access outcomes can help mon-
itor quality, guide changes in cannulation practice if
needed and improve the quality of vascular access care.
• AV grafts are usually only cannulated using sharp steel
needles.
Rationale
• Background
Sharp steel needles are routinely used for cannulating AV grafts
with a rope-ladder technique. In contrast, various methods are
used for cannulating AV fistulas. Besides differences in the loca-
tion and direction of needle insertion and differences in cannu-
lation technique, the shape of the needle (sharp or blunt, with
or without side or back holes) and the material of the conduit
(steel needle or plastic cannula)may influence AV access longevity.
Most units use sharp or dull steel needles, which remain in situ
during the dialysis session, providing a conduit for the blood flow
throughout each treatment. A sharp bevelled needle can cause
trauma to the vessel if inserted or placed incorrectly. It can even
perforate the AV fistula should the patient move inadvertently. In
some haemodialysis units, a synthetic cannula is inserted together
with a sharp steel introducer that is withdrawn once the cannula
sits within the vessel. The cannula is then used as the conduit dur-
ing the dialysis session. Other needling systems based on synthetic
materials also exist. Theoretically these synthetic needling systems
should result in fewer physical fistula injuries, but the benefits and
harms of these alternative systems require assessment.
• Summary of the evidence
(Supplement 3j Review questions—PICO Format—Chapter 10)
(Supplement 4j Search strategies—Chapter 10)
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(Supplement 5j Study selection flow diagrams—Chapter 10)
(Supplement 6j Summary evidence tables—Chapter 10)
Three RCTs assessing different needle designs were identi-
fied. One study, published only as an abstract, compared large-
gauge hollow-bore sharp steel needles (referred to in the study
as standard needles) versus Nipro SafeTouch sharp steel needles
(referred to as safety needles) [112]. The second RCT compared
sharp versus blunt steel dialysis needles using a buttonhole can-
nulation technique [113]. The third study compared plastic
cannulas with sharp needles using the rope-ladder technique
[114]. All three RCTs were conducted in a single centre and
reported outcomes after 1 and 6 months up to 1 year. Sample
sizes were generally small, including 33–39 participants.
All included RCTs reported outcomes considered relevant to
this guideline: cannulation difficulty or complications, needling
pain, infection, bleeding during or after dialysis, need for interven-
tions and patient preference. Outcome definitions and measures
varied. Two studies included prevalent haemodialysis patients
[112, 113] and one study included incident patients [114].
One RCT assessed a composite primary outcome of ‘acute
access-associated complications’, including needlestick injuries,
fistula ‘blows’ (not otherwise defined) and needle dislodgement
[112]. 39 participants were randomized to standard needles or
safety needles. No needle stick injuries occurred in either group.
In the standard needle group, 24 infiltrations—not otherwise
defined—occurred during cannulation and dialysis, while 15
infiltrations occurred in the safety needle group. According to
the authors, the result was not statistically significant, but no
analysis was provided.
A second RCT reported data after <1 month in 35 partici-
pants and 335 dialysis sessions [113]. Participants were ran-
domized at each session to have their AV fistula cannulated
using a buttonhole technique with a blunt needle or a sharp
needle. Resultant important carry-over between the interven-
tions made inference particularly challenging. Overall, among
169 AV fistula cannulations randomized to blunt needles, 12
were ultimately cannulated with a sharp needle due to failed
cannulation. Of the 166 AV fistulas randomized to sharp nee-
dles, four were ultimately cannulated with a blunt needle be-
cause the patient refused cannulation with a sharp needle or
experienced pain during cannulation. Overall, the difference in
failed cannulation was not statistically significant for the down-
stream needle. For the upstream needle, a blunt needle resulted
in cannulation failure more frequently than a sharp one (6%
versus 0%; P¼ 0.001). There were no meaningful differences in
needling pain, bleeding time or infection rate between the two
treatment groups [113].
A third study randomized 33 participants to have their AV
fistula cannulated either with plastic cannulas or sharp needles
[114]. Effects on the number of people having undergone a pro-
cedure for stenosis, thrombosis or aneurysm formation were
uncertain due to wide CIs and an imbalance in baseline event
rates. With plastic cannulas, there seemed to be 50% fewer
patients experiencing complications, defined as infiltration ei-
ther during cannulation or dialysis itself [RR 0.53 (95% CI
0.29–0.97)]. Again, however, the certainty of the evidence was
low due to sample size restrictions.
• Translation of the evidence into recommendations
The type of needle used for cannulation of an AV fistula has
very uncertain effects on patient and access survival. RCT data
are scant, making any inference for critical outcomes quite
problematic. Similarly, high-certainty data for quality of life
that could steer judgement in decision making are currently not
available. It appears that sharp steel needles less often result in
failed cannulation than blunt ones. In addition, the professed
benefit of less cannulation pain with blunt steel needles in but-
tonhole cannulation is not supported by current RCT data.
Unfortunately, those data are sparse. Only one very small trial
tested sharp needles in AV fistulas cannulated using the button-
hole technique, and the buttonhole technique was originally de-
scribed using blunt needles—the aim being not to injure the
cannulation tract [113].
There is only one small RCT assessing the proposition that
synthetic materials used for cannulation result in less damage to
the AV fistula vessel. Again, however, sample size limitations
prevent a preference of one material over another [114].
Other guidelines on this topic
The CSN, ESVS, GEMAV, KDIGO, NKF-KDOQI, KHA-CARI
andNICE provide no current recommendations on this topic.
Suggestions for future research
Adequately powered multicentre randomized trials assessing
the benefits and harms of sharp steel needles versus other nee-
dling systems using standardized outcomes would be informa-
tive. The currently available reports do not resolve the
uncertainty about long-term effects and incompletely describe
possible adverse events.
CHAPTER 11 . TIMING OF INTERVENTION
FOR AV FISTULA THROMBOSIS
Recommendations
We suggest attempting to declot a thrombosed arteriove-
nous ﬁstula in adults as soon as possible under optimal con-
ditions and before the next haemodialysis treatment. (2D)
We suggest attempting to declot a thrombosed arterio-
venous ﬁstula in adults, even if there has been a delay
of days to weeks. (2D)
Advice for clinical practice:
• None.
Rationale
• Background
Thrombosis of the AV fistula occurs quite often (one per
person every four years) and is one of the most frequent
causes of access failure (Helthuis et al., submitted for publica-
tion). Thrombosis causes vessel wall inflammation and struc-
tural injury to the vascular endothelium. On the assumption
that the longer a blood clot is present, the more damage it
inflicts, many consider an attempt at declotting the AV fistula
an emergency procedure to be performed as quickly as possible.
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However, such a strategy inevitably creates logistical challenges
and may inadvertently lead to worse outcomes if less experi-
enced operators must intervene in suboptimal conditions dur-
ing out-of-office hours. Understanding the trade-offs is the key
in decision making.
In AV graft thrombosis, the blood clot is relatively inert.
While it is widely agreed that a timely attempt at declotting the
AV graft must be made to avoid central venous catheters,
thrombosis is generally not considered an emergency.
Therefore this chapter only covers AV fistula thrombosis [115].
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 11)
(Supplement 4j Search strategies—Chapter 11)
(Supplement 5j Study selection flow diagrams—Chapter 11)
(Supplement 6j Summary evidence tables—Chapter 11)
There were no RCTs comparing the benefits and harms of
earlier versus later interventions for declotting a thrombosed
AV fistula.
There were four retrospective analyses assessing the effect of
time to intervention on outcome of the AV fistula [116–119].
All were inherently at very high risk of bias through selection,
attrition and failing to reach the optimal information size. AV
fistula outcomes were mostly reported in terms of technical suc-
cess and data on primary or secondary patency were largely
absent.
A first, nested case–control study including 188 AV fistulas
indicated that surgical thrombectomy within 24 h of diagnosing
thrombosis of the AV fistula resulted in 50% technical success
[116]. If deferred to any time during the first week, then only
20% of thrombectomy procedures remained successful. After
that, the probability of success dropped to 10%. The investiga-
tors provided univariable comparison data only and no attempt
was made to accommodate factors influencing clinical decisions.
A second, retrospective analysis included 59 people with
thrombosis of their AV fistula who had all been referred to vas-
cular surgery as quickly as possible [117]. Surgical thrombec-
tomy with percutaneous transluminal angioplasty or stent
placement resulted in technically successful declotting of the
AV fistula in 84% of participants treated within 6 h of diagnosis.
In those treated after that time, the procedure was successful in
74% [RR 1.14 (95% CI 0.87–1.49)]. Again, the comparison was
univariable with data unadjusted for possible confounding vari-
ables and CIs very wide.
In a third study, investigators retrospectively reviewed all 60
episodes of vascular access failure within a 3-year time frame
[118]. More than half were treated with thrombolysis, about a
third with a combination of thrombolysis and angioplasty and
one-tenth with angioplasty alone. When comparing interven-
tions executed within 48 h of diagnosis versus those performed
after 48 h, they found the odds of intervention failure to be
about half in the group with a 2-day delay versus the group in
which the intervention had occurred within 2 days [OR 0.55
(95% CI 0.31–0.99)]. This corresponded with an estimated
32% relative lower odds for access failure at 3 months [OR
0.68 (95% CI 0.36–1.27)]. The study included both AV fistu-
las and grafts. Although the analysis attempted to adjust for
possible confounders, interaction tests or subgroup data were
not available.
Finally, a group of investigators retrospectively reported
their experience with streptokinase intravascularly infused at
the site of the thrombosis [119]. Of the 19 participants treated
within 4 days of diagnosis, the procedure was successful in 16
(84%). For the eight treated afterwards, thrombolysis was suc-
cessful in three (38%) [RR 2.25 (95% CI 0.90–5.61)]. The sam-
ple size was small, cut-offs arbitrarily chosen and analyses
univariable.
• Translation of the evidence into recommendations
AV access failure is a common and serious complication leading to
increased temporary catheter use, access creation at multiple sites
and, after many years, of multiple access failures, to a catastrophic
inability to provide haemodialysis in some cases. Thrombosis is
one of the most frequent causes of access failure, and successful
declotting can save the access from permanent failure.
Intuitively, one would think that the earlier the intervention
(surgical or radiological) is undertaken, the more likely it will re-
sult in successful access salvage, as delay can only result in clot or-
ganization, retraction and fibrosis. Indeed, for this reason, many
have considered AV access thrombosis an emergency, necessitat-
ing immediate intervention. However, the evidence to support
this assumption is very sparse. There have been no randomized
trials assessing the effect of increasing the time to intervention
(within a reasonable time frame) on access outcome, and the ob-
servational data are limited and at high risk of being biased.
In addition, there may be biologic reasons for challenging
the existing paradigm. Given that acute thrombosis is associated
with vessel wall inflammation and endothelial injury, and such
early active inflammation may be prothrombotic in itself, it is
biologically plausible that some delay in intervention may in
fact avoid rapid recurrence of thrombosis after intervention.
Also, a recommendation favouring the shortest possible win-
dow for intervention may have important implications for ser-
vice delivery and health care resources. One of the included
studies assessed the causes for delay in intervention—the ma-
jority were due to the lack of interventional radiology unit avail-
ability [120]. A statement favouring rapid intervention could
also inadvertently lead to worse outcomes if less experienced
operators must intervene in suboptimal conditions during out-
of-office hours. Finally, most cases of access thrombosis are as-
sociated with an outflow stenosis, which may not be amenable
to surgical treatment. Adequate imaging of the inflow and out-
flow should be performed and thrombectomy and stenosis
treated simultaneously [120–123].
In the absence of a clear understanding of the trade-offs
at present, it seems reasonable that the timing of the intervention
is determined by different factors, including the urgency for a
functioning dialysis access and the availability of optimal logisti-
cal conditions to perform the best possible intervention.
Whereas there seems to be little data to support an aim for
the maximum time to intervention, the existing data support
intervention, irrespective of the time delay. Even after 2 days,
70% of procedures are still technically successful (correspond-
ing to a 3-month primary patency in 63%), and up to 1 week,
still about one in five can technically be salvaged [116, 118].
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This challenges the widely held view that late intervention is
likely to be futile. Modern mechanical thrombectomy devices
could be even more effective in restoring patency several days
after the thrombotic event [124, 125].
Other guidelines on this topic
ESVS [34]
We recommend that for vascular access salvage after early
thrombosis, thrombectomy and revision should be performed
as soon as possible. (IC)
NKF-KDOQI [86]
Thrombectomy of a fistula should be attempted as early as
possible after thrombosis is detected, but can be successful even
after several days. (B)
GEMAV [35]
We recommend a priority be placed on attempting to restore
the patency of potentially recoverable thrombosedAV fistulas, pref-
erably within the first 48h. In all cases, the priority should be to sal-
vage the AV fistula and avoid central venous catheter placement.
UK Renal Association [92]
We recommend that each centre should have facilities for
surgical and radiological intervention for prompt and timely
treatment of AV fistula/graft stenosis; a local standard policy
should be developed. (1B)
The CSN, KDIGO, KHA-CARI and NICE provide no current
recommendations on this topic.
Suggestions for future research
An adequately powered prospective observational trial
aimed at assessing standardized outcome measures according
to increasing time to intervention analysed as a continuous vari-
able could be informative for answering this question. An inte-
grated health–economic evaluation would be required to assess
the desirability of implementing the service change required to
meet a set maximum time-to-intervention threshold.
CHAPTER 12 . SURGICAL AND
ENDOVASCULAR INTERVENTIONS FOR AV
ACCESS THROMBOSIS
Recommendations
We suggest the choice between surgical and endovascu-
lar interventions for AV access thrombosis be deﬁned
by the condition of the patient and their vascular access
as well as local expertise, as there is no evidence one ap-
proach improves outcomes more than any other. (2B)
Advice for clinical practice:
• None.
Rationale
• Background
Traditionally an occluded AV access was always treated surgi-
cally. However, over the past 20 years, endovascular techniques
have increasingly been developed and are used as an alternative
to salvage thrombosed vascular accesses. Most centres tend to
prefer either surgery or endovascular intervention, depending
on and at the same time determined by local availability and ex-
perience with either technique. We aimed to determine which
interventions—surgical or endovascular—has the best risk–
benefit balance in the setting of AV access salvage, both for AV
fistulas and AV grafts.
• Summary of the evidence
(Supplement 3j Review questions—PICO format—Chapter 12)
(Supplement 4j Search strategies—Chapter 12)
(Supplement 5j Study selection flow diagrams—Chapter 12)
(Supplement 6j Summary evidence tables—Chapter 12)
Three RCTs were identified comparing either surgical versus
endovascular intervention or different types of endovascular in-
tervention with one another. Populations, interventions, com-
parators and outcomes varied across studies. All trials included
participants with AV grafts.
The first RCT compared the efficacy of a mechanical throm-
bectomy device (Amplatz) versus conventional surgical throm-
boembolectomy for declotting 174 thrombosed AV grafts
[126]. Between the 109 patients randomized to mechanical
thrombectomy and the 65 individuals treated with a surgical
approach, there was no difference in immediate thrombectomy
success and short- or long-term graft patency with successful
dialysis. No extensive details of differences in minor and major
adverse events between the two groups were provided.
Information on sequence generation (computer-based) was
given, but the study remained at unclear risk for most of the
other sources of bias. Of note, there was no information on
whether the surgical approach included construction of a new
anastomosis, that is, proximalization of the AV access.
The second RCT was a multicentre study including 120
adults with recently thrombosed AV grafts who were random-
ized to hydrodynamic thrombectomy (n¼ 62) or pulse spray
thrombolysis (n¼ 58), both endovascular procedures [127]. No
statistically significant differences were noticed in either techni-
cal success (as defined by 80% thrombus removal) or clinical
success (technical success plus being able to provide successful
dialysis) at 30 and 90days. Similarly there were no meaningful
differences in procedure-related blood loss and early or late
complications. Conversely, thrombus treatment times were
shorter for thrombectomy than for thrombolysis (16.8 versus
23.4min; P< 0.01), suggesting that hydrodynamic thrombec-
tomy could be useful for reducing treatment procedure time
with no impact on efficacy over thrombolysis. The study was
unclear with respect to selection bias, as no details were pro-
vided on randomization and allocation concealment. However,
there was a high risk of funding bias due to a declaration of in-
terest by one of the co-authors.
The third RCT randomized 40 patients with clotted AV
grafts to a lyse-and-wait technique with 4mg of the tissue plas-
minogen activator alteplase (n¼ 20) or to a percutaneous
thrombectomy device (Arrow-Trerotola), also both endovascu-
lar interventions [128]. In addition, 20 non-consecutive patients
with thrombosed synthetic AV grafts who were randomized to
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undergo the lyse-and-wait technique with urokinase
(250 000U) as part of an earlier clinical study served as histori-
cal controls. The immediate anatomic success rate was 95% in
both the tissue plasminogen activator lyse-and-wait and percu-
taneous thrombectomy device groups. The mean in-room time
until restored flow was significantly lower for lyse-and-wait
with tissue plasminogen activator than the percutaneous
thrombectomy device (10 versus 19min; P< 0.01), although
there were no differences in the mean in-room procedure time.
No bleeding complications occurred in the percutaneous
thrombectomy device group. Conversely, seven episodes of
bleeding occurred in 6 patients treated with tissue plasminogen
activator and 4 of the 20 patients undergoing lyse-and-wait with
urokinase had minor puncture site bleeding during the proce-
dure. The 3-month primary patency rates were 65, 65 and 60%
for lyse-and-wait with tissue plasminogen activator, percutane-
ous thrombectomy device and lyse-and-wait with urokinase, re-
spectively. Given the lack of information provided, the study
risk of bias remained unclear for most of the items considered.
• Translation of the evidence into recommendations
There is little randomized evidence available addressing this is-
sue. The three RCTs found were mostly designed to evaluate
the efficacy or superiority and safety of specific (endovascular)
techniques or devices rather than comparing, more generally,
surgical over endovascular approaches for AV access thrombo-
sis. In addition, no study compared any of the available proce-
dures in AV fistulas, all participants had AV grafts. Lastly,
surgical outcomes are biased if a new anastomosis, that is, prox-
imalization of the AV access, is included in the surgical treat-
ment. Observational studies suggest that thrombectomies with
adjuvant treatment to correct an underlying problem result in
better outcomes than endovascular intervention [129]. The ap-
propriate comparator is surgical balloon thrombectomy (with-
out altering the anastomosis) versus endovascular intervention.
Such a study has not been conducted. This heterogeneity of
procedures employed, type of interventions and comparators
and outcomes analysed prevent us from drafting definitive con-
clusions or recommendations favouring one approach over the
other.
Other guidelines on this topic
CSN [90]
Correct thrombosis of an AV graft with pharmacomechanical
or mechanical thrombolysis or surgical thrombectomy. (Grade D)
ESVS [34]
Surgery or endovascular methods should be considered for
treatment of late thrombosis of vascular accesses depending on
the centre’s expertise. (IIa-B)
Treatment of vascular access thrombosis should include
perioperative diagnosis and treatment of any associated steno-
sis. (I-C)
GEMAV [35]
We recommend an imaging test be carried out after restor-
ing AV fistula patency. This should be performed immediately
after thrombectomy to detect any possible stenoses requiring
treatment.
We initially recommend native AV fistula with thrombosis
secondary to juxta-anastomotic stenosis be treated by surgical
treatment as long as the technique does not require central ve-
nous catheter placement.
We recommend the patency of native AV fistula in throm-
boses not associated with juxta-anastomotic stenosis be restored
by surgical treatment or by endovascular therapy using me-
chanical thrombectomy or aspiration devices, if necessary.
We recommend it be attempted to restore the patency of
thrombosed prosthetic AV fistulas by surgical or endovascular
treatment.
We recommend elective intervention be performed on the
dysfunctional AV fistula with significant stenosis instead of re-
storing after thrombosis.
We recommend attempting to restore the patency of throm-
bosed AV fistulas rather than creating a new AV fistula and
place a central venous catheter, as this is associated with lower
health costs, lower hospitalization rates and lower morbidity
and mortality.
The KDIGO, NKF-KDOQI, KHA-CARI and NICE provide no
current recommendations on this topic.
Suggestions for future research
Given the lack of evidence proving the superiority of surgi-
cal over endovascular treatment for treating fistula thrombo-
sis, adequately powered RCTs providing data on the same
type of vascular access/problem (e.g. primary or recurrent
thrombosis, native fistula/grafts) and any type of procedure
would be highly informative. Studies should ideally target the
same core set of outcomes that should be considered essential
for answering this research question, such as targeted efficacy
endpoints (including but not limited to anatomic and clinical
success rate at established time points, procedure duration
and long-term patency with successful dialysis) and the safety
profile, particularly in terms of peri- and post-procedural
bleeding. Population selection and minimization of potential
biases are also crucial issues given the impossibility, due to the
nature of the intervention, of eliminating performance and de-
tection bias by blinding patients, investigators and outcome
assessors.
SUPPLEMENTARY DATA
Supplementary data are available at ndt online.
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